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Extracellular vesicles (EVs) are a group of heterogeneous plasma membrane-bound vesicles that 
are secreted by almost all cell types into extracellular space. EVs contain selected nucleic acids, 
proteins and metabolites that modulate biological activities after their internalization by recipient 
cells. Considerable efforts have been devoted to the study of EV-mediated communication among 
the cells. Such studies have demonstrated the importance of EVs in the spread of diseases.  
Pathological molecular cargos such as miRNA and proteins are shuttled via EVs into the 
circulation and are now known to be key players in progression of diseases. Therefore, isolating 
and subsequently accessing these bioactive vesicles can provide great insights into the diagnosis 
and prognosis of a patient’s pathological status. A critical caveat to the study of EVs is their 
extremely small size and the potential rarity of target EVs in a background of off-target EVs. The 
objective of this thesis is the study on the roles of EV in human disease and development of 
microfluidic technologies and protocols to advance the isolation and characterization of EVs 
First, an immuno-affinity based microfluidic device was introduced to study the role of EVs in 
amyotrophic lateral sclerosis (ALS). The device was adapted to isolate EVs from three types of 
tissues, namely serum, frontal cortex, and spinal cord from ALS patients and healthy controls. We 
compared miRNA cargo from diseased tissues including postmortem spinal cord and frontal cortex 
to healthy controls. As a result, we identified 60 miRNAs that are significantly altered in the patient, 
 xiii 
suggesting the possibility for use of EV miRNAs as biomarkers for ALS patients. The pathway 
analysis of miRNA targets also pointed the involvement of EV miRNAs in the ALS. 
Secondly, a microfluidic device, OncoBean chip is modified and optimized for high throughput 
EV isolation from cell culture supernatant and human plasma. The OncoBean Chip is a previously 
reported microfluidic device for isolation of circulating tumor cells (CTCs) with bean-shape 
microposts functionalized with biotin-conjugated EPCAM antibody. We modified this chip with 
the antibodies against common EV surface markers to achieve high throughput EV isolation. The 
high surface area provided by the bean-shaped miroposts and radial flow design facilitate capture 
of EVs not only at high flow rate (up to 10 ml/hr), but also form larger volumes of media form cell 
culture supernatant. Through desthiobiotin antibody capture and biotin elution, the device is able 
to release functional EVs from the device for cell uptake and identification of surface markers.  
Thirdly, to address the need for technologies for high-resolution analysis, we established a 
workflow for simultaneous mutation detection and gene expression profiling with low sample-
input. We developed the workflow from analyzing circulating tumor cells (CTCs) at a single cell 
resolution, aiming a future application to EV analysis. By integrating microfluidic technologies 
including the Labyrinth and Fluidigm C1 system, single CTCs from patients can be isolated and 
profiled for multiple characteristics. The feasibility of the workflow was validated with six non-
small-cell lung cancer (NSCLC) patient diagnosed with epidermal growth factor receptor (EGFR) 
mutation. The intra- and inter-patient heterogeneity observed in single lung CTCs from patients 













1.1 Extracellular vesicles 
Complex and well-orchestrated molecular mechanisms facilitate cell-to-cell communication, 
which is essential for cell functioning and the disruption of these mechanisms lead to disease.  In 
addition to hormones, the immune response, and neurotransmitters, extracellular vesicles are now 
recognized as an important source of cellular communication.  Extracellular vesicles (EVs) are 
lipid-bilayer-enclosed vesicles of 30-2000 nm in size that are secreted by most cell types into the 
extracellular space.1 These tiny vesicles are considered to be powerful mediators that carry the 
signaling machinery necessary to reprogram the functions and behavior of the recipient cells.2,3 
Many types of genetic information, including miRNA, mRNA, and DNA are found in EVs and 
have roles in many cellular functions.4 The transfer of these material have been proven to maintain 
biological activities after internalization by recipient cells.5,6 Furthermore, EV cargoes have proven 
to be involved in the pathological progression of various types of diseases, making them the new 
possible biomarkers and therapeutic targets.7-9 Therefore, due to their potentials as biomarkers for 
disease and application for therapeutics, the biological roles and clinical applications of EV is now 
widely investigated. 
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Based on the size and biogenesis, EVs are commonly categorized into three major subtypes: 
exosomes, microvesicles, and apoptotic bodies (Figure 1.1). Exosomes are vesicles of 30-200 nm 
in size that are formed intracellularly by the inward budding of cellular compartments known as 
multivesicular endosomes (MVE) and released to the extracellular space by the fusion of MVE 
with the plasma membrane.10,11 Microvesicles are shed by direct budding of the plasma 
membrane.12 Apoptotic bodies are generated and released during programming cell death.13 
Notably, there are still controversies in the nomenclature and size definition of different population 
of EVs, especially for microvesicles and exosomes.2 This arises from overlaps in the biophysical 
characteristics and protein markers among the subtypes of EV. Although the International Society 
for Extracellular Vesicles (ISEV) has published a Minimal Information for Studies on EVs 
(MISEV) guidelines, there is still not a well-defined classification that encompasses the 
heterogenous EV populations.14 
 
Figure 1.1 Schematic representation of extracellular vesicles.  
Generally, EVs can be classified into three categories. Exosomes (30-200nm) are formed by the 
inward budding of multivesicular bodies (MVE). MVE can fuse with the plasma membrane of the 
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cell and release the exosomes into extracellular space. Microvesicles (100-1000nm) are formed by 
direct budding of the cell membrane. Apoptotic bodies (100-2000nm) are released from apoptotic 
cells 
Technically, the study of EVs is not a new field. Several decades ago, EVs were discovered  and 
were thought to serve as  shuttles for cells to get rid of unnecessary proteins and nucleic acids that 
were not able to be degraded by the cell’s lysosomal system.3  However, accumulating evidence 
has shown that EVs contain specifically selected RNAs, proteins, and metabolites that are 
representative of their originating cells, suggesting an important role as mediators in cell-to-cell 
communication.15-17 For instance, Valadi et al. demonstrated the presence of EV mRNAs, which 
can be transported to target cells where they are translated into proteins.6 EVs are largely released 
in body fluids and taken up by the specific recipient cells where they release their cargo. These 
cargoes have proven to be involved in prognosis of tumors and other pathologies, such as 
neurodegenerative diseases.18-20 Therefore, the identification and characterization of EV cargo can 
provide valuable information about biological function as well as the detection, characterization, 
and monitoring of disease progression. 
1.2 EVs and their role in cancer  
Accumulating evidence have demonstrated the vital roles of EVs as mediators between tumor and 
tumor environment.21,22 Various biomolecules, including proteins, lipids, metabolites, RNA, and 
DNA, carried by EVs throughout the circulatory system can be involved in cancer growth, 
metastasis and dissemination.23,24 Therefore, the ability of EVs to shuttle the tumorigenic 
information from one cell to another and alter the behavior of the recipient cells makes them a 
promising tool for understanding and uncovering molecular mechanisms to cancer biology.  Zhao 
et al. demonstrated that EVs secreted from cancer-associated fibroblasts could be taken up by 
pancreatic adenocarcinoma cells and upregulate their proliferation by inhibiting mitochondrial 
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oxidative phosphorylation.21 Furthermore, the rich supply of metabolites in found inside EVs from 
fibroblasts can also act as a pool to supply the nutrient for cancer cells.21 Similar observations were 
also reported for other types of cancer. EVs derived from fibroblasts in breast cancer stroma 
enhance cancer motility and metastasis by alternating autocrine Wnt-planar cell polarity (PCP) 
signaling.25 Khazaei et al. have shown that miR-451 transferred by EVs from cancer-associated 
fibroblasts contributes to the migration and progression of esophageal cancer.26  
Additionally, tumor cells can also alter the microenvironment via EVs to promote tumor 
proliferation, angiogenesis and metastasis.27,28  Transforming growth factor β transferred by 
mesothelioma-derived EVs was found to induce the myofibroblast differentiation.29 MiR-1247-3p 
shuttled by the EVs secreted by high-metastatic hepatocellular carcinoma cells can alter 
inflammatory genes in fibroblasts, promoting lung metastasis.30 Moreover, the influence of tumor-
derived EV is not limited to local tumor microenvironment.  Melanoma-derived EVs are able to 
promote vascular leakiness at future metastasis sites by influencing bone-marrow progenitors.31 
EVs secreted by pancreatic cancer cells can induce pre-metastatic niche formation in the liver.32 
In total, studying the role of EVs and their associations with tumorigenesis can really provide 
opportunities to analyze the biological principles underlying the progression of cancer. 
In addition to the contribution of EVs in pathological development, studies have also highlighted 
the significance of EV as diagnostic tools for cancer. Due to the presence of EVs in virtually all 
types of body fluid, EVs are viewed as potential resources of easily-accessible biomarkers.33,34 For 
example, EVs in peripheral blood has been extensively investigated for cancer detection.  Melo et 
al. have shown that measuring the levels of tumor-derived EVs has a superior specificity and 
sensitivity as a diagnosis tool compared to the measurement of the levels of carbohydrate antigen 
19-9 (CA19-9), the clinical standard pancreatic adenocarcinoma biomarker.35 Fu et al. observed a 
 5
higher concentration of EVs in serum of gastric cancer patients comparted to healthy controls.36  
In addition to the total concentration, the proteomic and genomic cargos of EVs have gained 
significant interest as potential biomarkers. Fibronectin, one type of extracellular matrix protein, 
in EVs has been shown to be a sensitive marker to detect early stage of breast cancer.37 Niu et al. 
demonstrated the diagnostic value of EV-derived alpha-2-HS-glycoprotein in serum for non-small 
cell lung cancer.38 Hao et al. reported the high sensitivity of EV mRNA in serum to detect the 
kirsten rat sarcoma viral oncogene homolog (KRAS) and B-raf serine/threonine kinase proto-
oncogene (BRAF) mutation in patients with colorectal cancer.39 Notably, the miRNAs in EV have 
also attracted the attention in cancer biomarker. The dysregulation of EV-derived miRNA in body 
fluids has been identified in various types of cancer, including bladder, brain, pancreatic, breast, 
and lung cancer.40,41 For instance, EV miR-21 in the CSF are found to be significantly upregulated 
in glioma.42 Bryant et al. showed that the abnormal levels of miR-141 and miR-375 in serum-
derived EV can be a marker for the metastasis in prostate cancer.43 In total, it is believed that that 
studying the role of EV and their associations with tumorigenesis can  provide opportunities to 
analyze the biological principles underlying the progression of cancer. 
1.3 EVs and neurodegenerative diseases 
Neurodegenerative diseases are a devastating class of diseases caused by the progressive loss of 
function or structure of neurons and, in most cases, no efficient cures and therapies are available. 
Several neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease (AD), and 
Amyotrophic lateral sclerosis (ALS) are classified as proteopathies, meaning the 
neurodegeneration is associated the with overexpression or aggregation of misfolded protein.44,45  
Research has suggested that the misfolded proteins might trigger synaptic dysfunction and neuron 
 6
apoptosis, leading to neurodegeneration.46 However, the propagation mechanism of these 
pathological proteins across the cells and tissues are still poorly understood. 
Recently, the association between EV and neurodegeneration has attracted special interest in the 
field. EVs have been shown to transport biological molecules, including protein, DNA and RNA, 
throughout the human body, facilitating cell-to-cell communication over long distances. The cargo 
carried by EVs has been demonstrated to support crucial cellular functions in CNS such as neurite 
outgrowth, synaptic activity and immune functions.47-49 Additionally, recent studies have shown 
the ability of EVs to transfer across the blood brain barrier, suggesting that they facilitate 
communication between the peripheral tissues and central nervous system (CNS).50,51  In addition 
to normal cellular functions, accumulating evidence has also suggested the important roles of EVs 
in the spread of pathological proteins and nucleic acids related to neurodegenerative diseases.19,52 
Considerable efforts have been made to decipher the roles of EVs in various types of 
neurodegenerative diseases. 
1.3.1  EVs and Alzheimer's disease 
Alzheimer's disease (AD) is one of the most common type of neurological disorder in which the 
progressive death of brain cells causes cognitive and behavioral impairment.53 Although the major 
causes of AD still remain unclear, it is widely accepted that neuron death in AD is the direct 
consequence of either the aberrant accumulation of amyloid-β or abnormally hyperphosphorylated 
tau protein.54 Growing evidence have suggested that EVs are the mediators of these two 
pathological proteins, regulating the AD pathogenesis. It was recently shown that the amyloid-β 
are released to extracellular space brains via EVs.55   Saman et al. reported that tau can be released 
by neuroblastoma cells through EVs.56 Furthermore, they also found that EV-derived tau is the 
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major source of CSF tau in patients, suggesting the involvement of EV in abnormal processing of 
tau in AD pathogenesis. In addition to proteins, several studies have suggested the potential of 
dysregulated miRNAs in EV as AD biomarkers.  Abnormal levels of miRNAs in EV are observed 
in pathogenesis of many diseases including AD.53 For instance, using Illumina deep sequencing, 
Lugli et al. performed miRNAs profiling on the plasma EV. They identified 20 dysregulated EV 
miRNAs, and seven of them can predict AD status with 83–89% accuracy.57 All these findings 
indicate the essential role of EVs in AD propagation as well as their diagnostic value. 
1.3.2  EVs and Parkinson’s disease 
Parkinson’s disease (PD) is another common neurodegenerative disease characterized by the 
progressive death of dopaminergic neurons in the substantia nigra of brain.58,59 The loss of 
dopaminergic neurons can result in motor deficiency and cognitive impairment in PD patients.60 
The aggregation and misfolding of α-synuclein protein have been associated with the death of 
dopaminergic neurons.61 Emerging evidence has pointed to the involvement of EVs in the spread 
of pathological α-synuclein between neurons.62 For instance, Emmanouilidou et al. demonstrated 
the secretion of α-synuclein by EVs in cell cultures and confirmed their influence on the 
neighboring neurons.63 The α-synuclein in EVs has also been identified in various types of body 
fluids in PD patients, such as CSF, saliva, and blood.64-66   Stuendl et al identified the presence of 
α-synuclein in EVs from CSF of PD patients.64 They also showed that the level of EV α-synuclein 
in CSF can be biomarker for PD and dementia. Furthermore, the altered miRNA cargos shuttled 
by EV have also been considered as potential biomarkers.  Cao et al. analyzed the miRNA content 
in EV isolated from serum and identified significant dysregulations of miR19b, miR24 and 
miR195 in patients with PD.67  Therefore, profiling and analyzing EV cargos can provide valuable 
information to elucidate the progression and to find the biomarkers for PD. 
 8
1.3.3  EVs and ALS 
ALS is a phenotypically and genotypically heterogeneous, terminal neurodegenerative disease 
characterized by motor neuron death and muscle atrophy.68 ALS is thought to develop as a non-
infectious prion-like disease. The misfolded proteins, such as transactive response DNA binding 
protein 43 (TDP-43) and superoxide dismutase 1 (SOD1), are found to be aggregated in motor 
neurons before neurodegeneration.68,69 Some of these misfolded proteins, which have the ability 
to propagate by inducing misfolding of normal proteins like a prion, and are speculated to be the 
main cause of ALS.70 Clinical and molecular observations indicate that motor neuron death 
proceeds in a patterned manner and pathological protein aggregates are secreted and then taken by 
other neuron cells.71,72 However, the mechanisms underlying these processes are not fully 
understood.  
The ability of EVs to carry information from one cell to another and promote the transportation of 
biological molecules can provide great opportunities to understand this intracellular transfer in 
ALS. Furthermore, in the nervous system EVs transport molecules between neuronal and non-
neuronal cells and the cargo shuttled via EVs are able to cross the blood-brain barrier.73 The 
discovery of pathogenic molecules, such as misfolded SOD1 and TDP-43, and the small RNAs 
(miRNAs) in EVs strongly imply the involvement of these vehicles in pathogenesis of ALS.70,74 
Thus, it is engaging to investigate the biological role and clinical relevance of circulating EV in 
ALS 
1.4  EV isolation 
High-purity EV capture would facilitate studies in EV biology, ranging from diagnostic 
applications to physiological functions.  Additionally, high purity will reduce noise from 
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contaminating protein aggregates, thus leading to highly specific protein analysis. Conversely, 
contamination with non-vesicular proteins or other extracellular vesicles can lead to generation of 
false data and incorrect conclusions.       
Many studies have focused on the enrichment and identification of EVs from body fluids for 
downstream analysis. Each of them exploits EVs’ biochemical properties or physical properties, 
such as size, density, surface charge, and surface marker to separate EVs from interfering 
components in the sample.75 The ideal technology should exhibit high efficiency isolation and 
enable downstream analysis to characterize the size, quantity, and cargos of EVs. Although several 
methods have demonstrated the ability to isolate EVs, they have associated drawbacks that can be 
improved upon.  
1.4.1 Conventional EV isolation 
1.4.1.1 Ultracentrifugation and ultrafiltration 
Ultracentrifugation is the most common technology used for concentrating EVs, often in 
combination with sucrose density gradient that allows the relatively low density EVs to separate 
from the pellet (Figure 1.2A). It is a proven method which is used extensively to isolate EVs from 
multiple sample types including urine, whole blood and CSF.76 However, the procedure is quite 
lengthy and the cumbersome protocol, which includes a series of centrifugations, requires a high 
amount of labor.76,77 Additionally, the yield is relatively low as a result of material loss during the 
processes.78  
Due to the fact that EVs are much smaller than other extracellular vesicles, isolation of the EVs 
based on size like ultrafiltration is a reasonable option (Figure 1.2B). The commercial kit ExoMir 
launched by Bioo Scientific take advantage of this size difference and uses two syringe filters to 
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capture the EVs and extract the RNA.79 After the serum is pushed through the filters, the first filter 
removes the apoptotic bodies and microvesicles while the second filter captures all vesicles of 
diameter greater than 30 nm. Compared to ultracentrifugation, this method is relatively fast and 
easier to operate.   Although the RNA from the EVs can be extracted from the second filter by 
lysing the captured vesicles with the provided reagents, the method is not able to reclaim purified 




Figure 1.2 Conventional EV isolation techniques.  
(A) Ultracentrifugation (UC) is the most common method for EV isolation. Series of centrifugation 
with increasing speed separates different size of EVs from the debris. (B) Ultrafiltration separates 
the EV by sizes. The non-vesicular debris are sieved from the EVs with filters. (C) Precipitation-
based isolation ultlizes precipitants like PEG to concentrate all the particles in the samples. After 




1.4.1.2 Polymer-based precipitation  
Precipitation-based technology is also commonly used for EV isolation. Typically, the introduction 
of the precipitant reduces the solubility of particles in the sample, and therefore the particles will 
sediment into pellets (Figure 1.2C). Although the application of this principle in isolating EVs is 
relatively new, commercial kits like ExoQuick and Total Exosome Isolation have demonstrated 
fast recovery of EVs from different body fluids.80,81 Compared to the abovementioned techniques, 
these kits are easy to use and do not require advanced equipment. A complication is that the non-
vesicular proteins can be co-isolated into the prep after precipitation, leading to contamination. It 
has been reported that although the yields of the RNA and proteins by precipitation is high, most 
of them are not from EV, which cause unwanted noise in the downstream analysis.82  Therefore, 
an efficient and reproducible isolation method that supports the downstream analysis and clinical 
utilization of EVs is still necessary. 
1.4.2 Microfluidic-based approaches s 
In the past few years, microfluidic technologies have garnered special interest in their application 
to concentrate or isolate EVs. Microfluidic devices have enabled the development of 
unprecedented applications for medical diagnostics and body fluid analysis.83,84  These devices 
have very small dimensions, facilitating minimized reagent volumes, isolation time, and 
procedural costs while enhancing the product purity and sensitivity.83,84 Microfluidic isolation 
technologies are categorized by their use of  i) physical or ii) chemical properties to isolate the 
EVs. The former isolates the EV based on their size, density, and surface charge while the latter 
relies on the expression of surface markers on EVs.  
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1.4.2.1 Physical-propertiy based approach 
The use of EVs’ physical properties allows for a label-free isolation, which overcomes biased EV 
selection based on specific biological properties. Furthermore, isolating EVs with label-free 
approaches typically avoid chemical binding to the surface of EVs, which permits greater 
flexibility for downstream characterization and use of EVs. Examples of these technologies 
include deterministic lateral displacement, microfilters, and nanowire trapping. 
One such example was reported by Wunsch et al.85 They devised a deterministic lateral 
displacement (DLD) device that enriched small EVs based on the size. The device was fabricated 
by silicon processes to produce a pillar array of uniform gap sizes, which determines a critical 
diameter Dc. Upon injection of the samples, particles with a diameter larger than Dc are displaced 
laterally and pushed to the side of the devices while the small EVs passed through device with 
streamlines of the fluid into the collecting channel. Similar system was also reported by Santana 
et al. Their DLD device can achieved high purity isolation of EVs (98.5 %), however with a low 
recovery efficiency. Although these devices demonstrated the isolation of selected size ranges EVs, 
they lacked performance evaluations with clinical samples to demonstrate the clinical applications.   
Wang et al. constructed a silicon nanowire with ciliated micropillar structures to trap vesicles 
ranging from 80 to 120 nm in diameter.86 In operation, the porous microstructure of the pillar can 
capture the EVs while filtering out proteins and debris. Post capture, the immobilized EVs can be 
harvested by dissolving silicon nanowire with buffer solution. The authors demonstrated the ability 
of the device to isolate and harvest the small lipid vesicles (83 and 120 nm) from large polystyrene 
beads (500nm). However, the performance of the device was only validated with pre-purified 
vesicles and beads. Optimization with clinical samples and subsequent characterizations of the 
captured EVs are necessary for this approach.  
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Microfluidic filtration is another label-free EV separation technique. Generally, the microfluidic 
device is implemented with the nano-porous membrane with the pore size ranging between 100 
and 1000 nm to separate different population of EVs from samples. For instance, Davies et al. 
developed a PMMA-based membrane sieve driven by pressure force applied by syringe pump to 
filter the EV from the blood sample.87  In the cross-flow mode, the DC electrophoresis was used 
as an alternating driving force to push the particles across the membrane while sample and 
collection lines were injected at equal flow rates, preventing the clogging of pores. Liu et al. 
devised the Exosome Total Isolation Chip (ExoTIC), which targets small-sized EV.88  The 
polyethersulfone (PES) filter sealed in the plastic gaskets separates the EVs from free nucleic acids, 
lipids, and other contaminating fragments. The clinical utility of the chip was also evaluated by 
applying different types of clinical sample, including plasma, urine, and lavage.  
Although advancements in size-based and other physical separation approaches have allowed 
label-free isolation of EVs, they generally still suffer from limitations related to heterogeneity of 
EVs, the complexity of body fluids, and low throughputs. The contamination with cellular debris 
and proteins cause lower specificity and purity compared with the chemical properties-based 
systems. Moreover, these label-free technologies typically need pre-processing steps such as 
dilution and centrifugation prior the isolation, limiting their utilities in processing clinical samples. 
1.4.2.2 Immuno-affinity approach  
Immuno-affinity capture based microfluidic devices for EV capture serves as a superior approach 
for the specific isolation of target EVs.  Typically, the immuno-affinity approach exploits selective 
antibody-antigen binding to capture vesicles based on surface antigens and extract them from body 
fluids, allowing for the specific and selective capture of extracellular vesicles of interest.89,90  EVs 
from virtually all cell types are highly enriched in the tetraspanins family of proteins, including 
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CD9, CD63, CD81, and CD82.91 The overexpression of these surface markers on EVs enables the 
capture of EVs with high selectivity by the corresponding antibodies.  
Chen et al. led a pilot study that incorporated an immuno-affinity based microfluidic device for 
EV capture from plasma samples of pancreatic cancer patients.90 The polydimethylsiloxane 
(PDMS) chamber of the chip was conjugated with anti-CD63 that captures EVs upon sample 
injection. The device allows for the recovery of RNA and protein cargo from EVs by injecting 
corresponding lysis reagent, demonstrating its potential for clinical application.( PMID: 20126692) 
This technology was further advanced by Kanwar et al who also used an anti-CD63 capture 
microfluidic device, but then also used fluorescent dye to stain the captured EVs to achieve an on-
chip EV quantification.89 Zhang et al. developed a microfluidic chip that contains 3D graphene 
oxide (GO)/polydopamine (PDA) microposts coated with capture antibodies. They demonstrated 
the use of the chip for studying EVs from ovarian cancer.92 Chen et al. designed an integrated 
microfluidic system that isolates EVs directly from human whole blood with magnetic beads 
coated with anti-CD63.93 The system incorporates a membrane-based filtration module for pre-
isolation of the plasma from whole blood. This was followed by the introduction of magnetic beads 
to the plasma for subsequent purification of EV under a magnetic field. The system is also 
integrated with on-chip enzyme-linked immunosorbent assay for on-chip EV quantification.  
Notably, EVs are heterogeneous collections of vesicles secreted by cells; based on the cell origin, 
each subgroup of EVs can have distinctive combination of surface markers. In addition to the 
tetraspanins family, different markers such as epithelial cellular adhesion molecule (EPCAM) and 
annexin have also been used for capturing specific EV populations. Dudani et al. designed a 
microfluidic platform that allows rapid isolation of EVs with magnetic beads coated with anti-
EPCAM and anti-CD63. The device utilized the inertial lift forces induced by the rapid inertial 
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solution exchange to focus the EV-beads complex to collecting streamlines, achieving high-
throughput enrichment of EVs from the waste components.94 Kang et al. demonstrated the EV 
capture from blood of patients with non-small cell lung cancer (NSCLC) and melanoma using 
annexin V antibody.95 They also showed that compared to CD63 antibody, annexin V antibody 
had a higher efficiency for EVs capture in non-small cell lung cancer.  
In addition to surface protein, recent studies have shown that EVs have specific lipid composition 
signatures depending on their parent cells.96 The enrichment of lipids, such as cholesterols, 
sphingomyelins and phosphatidylserine in EVs have been demonstrated.97 Therefore, lipids on the 
plasma membrane of EVs have also been considered as potential targets for affinity-based isolation. 
Wataru et al. demonstrated the isolation of small EVs using magnetic beads conjugated with T-
cell immunoglobulin mucin protein 4 (Tim-4) that captures the phosphatidylserine (PS) in the EV 
plasmas membrane.98 With similar capture strategies, Huiying et al. devised a microfluidic 
platform, ExoPCD-chip, that isolates EVs with Tim-4 magnetic beads from serum.99 
1.5 EV characterization  
EV analysis offers valuable insights into pathogenesis and diagnosis of diseases. However, due to 
the extremely small size of EVs and the potential rarity of target EVs in a background of off-target 
EVs, such analysis can face technical and analytical challenges. With an increasing need for EV 
cargo characterization in biomedical research, numerous technologies have been developed for 
concurrent EV detection and cargo characterization.  For instance, Ye Hu and colleagues describe 
a nanoparticle-enhanced scattering assay that enables the detection of EVs in blood plasma with 
high sensitivity and specificity and demonstrate its use in the diagnosis of pancreatic 
adenocarcinoma, with performance superior to the standard clinical biomarker.100 Si-Yang Zheng 
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and colleagues report a lipid-nanoprobe approach that allows for the rapid, cheap and efficient 
isolation of nanoscale EVs, and that enabled the identification of DNA mutations in the genetic 
material of plasma-derived EVs isolated from non-small-cell lung cancer patients.101  
Methods for characterizing EVs can be classified into biochemical and biophysical analysis 
approaches. Biophysical methods characterize the concentration, size distribution and morphology 
of EVs while the biochemical approaches analyze biological composition of EV and their contents 
including, nucleic acid, protein and lipids.  
1.5.1 Biophysical approaches s 
The biophysical analysis of EVs is typically done by nanoparticle tracking analysis (NTA), 
scanning/transmission electron microscopy, and atomic force microscopy. 
1.5.1.1 Nanoparticle tracking analysis (NTA) 
In NTA, the motion of EVs in the suspension is tracked by measuring the scatter of laser signals 
corresponding to EV motion. The NTA software analyzes the motion trajectories of the EVs and 
estimate the concentration and size based on the counts of particles per frame and Stokes–Einstein 
equation, respectively.102 The detection range of NTA is between 10 and 1000 nm in diameter, 
which is suitable for EVs measurement. NTA is one of the most commonly used method to 
determine the concentration and size distribution of the EVs.102,103 Commercial NTA instrument 
is available and easy to operate. However, NTA is not capable of discriminating EVs from other 
nanoparticles in the suspension. Although fluorescently labeling with antibody or membrane dye 
can be a possible solution, the measurement is still hindered by the noises from the excess dye.103  
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1.5.1.2 Scanning/transmission electron microscopy (SEM/TEM) 
Electron microscopy (EM) is a commonly used technique for directly measuring the size and 
morphology of EVs. SEM accesses the specimen by scanning a focused electron beam onto the 
specimens. The interactions between the primary beams and the atoms on the surface of specimens 
results in the emission of secondary electrons. The images are then obtained by collected and 
translated these secondary electrons. Instead of detecting the secondary electrons, TEM depends 
on the transmitted electrons, the electrons that pass through the specimen, to produce an image. 
Since the wavelength of electrons is much shorter than visible light, SEM and TEM provide higher 
resolution than light-scattering techniques like NTA.104 Moreover, EM coupled with immunogold 
labeling has proven to be useful to the identification of the markers, such as proteins and antigens, 
on EVs.105 One of the limitations for EM is the sample preparation, which involves fixation and 
series of dehydration steps.106 These steps can potentially alter the shape and size of EVs. 
Furthermore, EVs can be damaged by the high-voltage electron beams during the EM 
measurement. 
1.5.1.3 Atomic force microscopy (AFM) 
AFM is another powerful, high-resolution microscopy technique that allows for characterization 
of EV-sized nanoparticles.107 AFM scans the interactions between a sharp probe tip at the end of 
a cantilever and the surface of specimen. The deflection of the probe tip caused by interaction 
forces is monitored by recording a laser beam reflected off the back of cantilever. The reflected 
laser beam is detected by a position sensitive detector to image the topology of the surface.108 The 
most appealing feature of AFM is the ability to operate in normal conditions, such as air and liquids 
while EM requires vacuum condition for high-resolution imaging. Therefore, compared to EM, 
AFM prevents the fixation and drying procedure for sample preparation, which retains the shape 
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and surface structure of EVs.  Like EM coupled with immunogold labeling, AFM is also able to 
examine the biochemical properties of EVs by introducing probe tips functionalized with 
antibodies. For instance, Sharma et al. reported the use of AFM to detect the CD63 antigens of 
EVs from saliva samples with probe tips functionalized with antiCD63.109  
1.5.2 Biochemical approaches 
Biochemical approaches analyze EVs to determine their protein or nucleic acid composition, either 
DNA or RNA.  EVs harbor disease-related genetic and proteomic information, which can provide 
valuable insights to the disease progression 
1.5.2.1 EV protein analysis  
Flow cytometry  
Flow cytometry is a commonly used technique that analyzes the surface protein markers expressed 
on EVs via fluorescent-conjugated antibodies.110 Although flow cytometry provides high-
throughput measurements and quantification of EV, it has a 300–400 nm limit of detection for 
sample diameter.111 The scattering light signals of smaller-sized EVs are missed due to its overlap 
with background instrument noise. To overcome this limitation, beads coated with antibodies are 
often used to capture EVs and act as carriers for the flow cytometry analysis.110  However, this 
method can potentially underestimate the concentration of EVs due to the multiple binding of EVs 
on the bead. Recent advance in flow cytometry have improved the detection limit, making the 
direct measurement on EVs possible. For instance, imaging flow cytometry (IFCM) has been 




Immunoblotting and enzyme-linked immunosorbent assay (ELISA) 
Immunoblotting, also known as western blotting, is an established technique for identification of 
EV proteins.103 Typically, the lysis buffer containing protease inhibitors is used to lyse the plasma 
membrane of purified EVs and release the protein. After dilution with loading buffer and 
denaturation by heat, the protein lysate is separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). The specific proteins can then be targeted with corresponding 
primary antibodies. The secondary antibody that recognized the host species of the primary 
antibody are then applied to bind the antigen of the primary antibody. The proteins are then 
identified by detecting the enzymes, such as alkaline phosphatase or horseradish peroxidase groups, 
conjugated on the secondary antibodies. Immunoblotting is a well-accepted method to verify the 
existences of EVs in the samples by detecting the presence of common EV markers such as CD9, 
CD63, CD81, Tsg101, and heat shock proteins.113 Despite the simple procedure and reliable 
detection, immunoblotting requires potentially unachievably high concentrations to achieve 
detectable concentrations. This is a drawback in EV analysis since purification of EVs typically 
needs lots of samples and time. Furthermore, it lacks the ability to quantitatively analyze the 
proteins.  
Enzyme-linked immunosorbent assay (ELISA) is a commonly used method to detect and quantify 
the proteins of EVs. The principle of an ELISA is similar to the immunoaffinity approach. The 
protein markers on the EVs are recognized and captured by the matching antibodies coated on the 
supporting substrates (usually polystyrene plates). These antibodies can be directly labelled with 
an enzyme or indirectly labelled with enzyme-conjugated secondary antibodies. The presence of 
EV proteins can then be verified by detecting the fluorescent or color change of the substrates 
triggered by these enzymes. Compared to immunoblotting, ELISA can provide a quantitative 
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information of the protein of interest. Furthermore, the ELISA is also a widely used technique to 
isolate EVs.103 Commercial kits, such as ExoELISA and ExoQuant™, are available. 
1.5.2.2 EV nucleic acid analysis  
EVs harbor nucleic acids including DNA, RNA, and miRNAs that have been shown to be 
prognostic and diagnostic of many diseases, along with allowing for biological studies of EVs. 
Analyzing these cargos can be challenging, with the heterogeneity and limited amount making 
analysis extremely difficult. Technologies with high sensitivity and efficiency are required to 
examine the composition of nucleic acids in EVs.  
Digital PCR  
Digital PCR (dPCR) is a highly sensitive technology which enables detection and quantification 
of nucleic acid sequences. In dPCR, individual nucleic acid molecules are compartmentalized into 
an individual droplet through water-in-oil emulsion such that each droplet carry either no 
molecules or only a single molecule. Each droplet acts as an individual reaction vessel and the 
nucleic acid molecules are amplified and analyzed in parallel by performing standard PCR 
amplification (Figure 1.3). Unlike classical real-time PCR, the quantification of nucleic acids can 
be achieved solely by counting the fluorescence signals of each droplet using TaqMan or SYBR 
green assays, and thus producing highly sensitive mutation detection. Several studies have 
demonstrated the ability of dPCR to quantify and detect the nucleic acid cargos of EVs. For 
instance, Zhang et al. used dPCR to evaluate the performance of their microfluidic device by 
quantifying the mRNAs in captured EV.114 Wang et al. compared the performance of dPCR and 
conventional qPCR with miRNAs of urinary EVs.115 They reported that compare to conventional 
qPCR, dPCR has a higher sensitivity and consistency with diluted samples. Chen et al. 
demonstrated the use of dPCR to identify and quantify the mutated transcripts in EV mRNA from 
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CSF of glioma patients.116 DPCR has been shown to be a fast and easy-to-use technique to detect 
the abundance in nucleic acid sequences with high sensitivity and specificity. However, dPCR is 
only able to detect known targets in the sample by choosing the corresponding assays. Furthermore, 
it is a low-throughput method as each test only allows for no more than 12 samples. Therefore, 
dPCR has been used as validating or monitoring method after the targets are determined by large-
scale molecular technologies like sequencing. 
 
Figure 1.3 Schematic workflow of digital PCR (dPCR).  
In dPCR, individual target molecules are compartmentalized into a individual droplet through 
water-in-oil emulsion such that each droplets carry either no molecules or only a single molecule. 
Each droplet acts as an individual reaction vessel and the target molecules are amplified and 
analyzed in parallel by performing standard PCR amplification. Unlike classical real-time PCR, 
the quantification of the target molecules can be achieved solely by discriminating the fluorescence 
signals of each droplet using probe assays such as Taqman and SYBR green. 
 
Next generation Sequencing (NGS) 
NGS is a high-throughput, reliable technique for quantitative characterization of mRNAs and 
miRNAs in EVs. It provides a comprehensive analysis on molecular signatures of mRNA and 
miRNA in EVs at single-base resolution. Typically, the small RNAs or miRNAs are reverse 
transcribed to cDNA molecules, followed by attaching the adapters or linkers to prepare the cDNA 
library with PCR amplification. The sequencing data are then generated with an NGS technology 
by aligning the sequences in the library with reference genome to determine the abundance of each 
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sequences in the sample. Several studies have demonstrated the use of NGS to identify aberrant 
mRNAs and miRNAs in EVs from various type of build fluids such as serum, urine, and CSF.117 
For instance, Rodríguez et al. isolated miRNAs from urinary EVs from prostate cancer patients 
and identified 5 dysregulated miRNAs using NGS.118 Jin et al. identified several EV miRNA 
markers in serum for non-small cell lung cancer with NGS. They also demonstrated the diagnostic 
value of EV miRNAs to discriminate different subtypes of non-small cell lung cancer.119 The main 
drawback of NGS is the potential bias caused by the amplification during the library construction. 
The bias between different library preparation protocols were also reported.120 Furthermore, 
depending on the EV isolation method used, NGS can also be biased by non-vesicular 
contaminates remaining in the samples.121  
Nanostring 
NanoString is a digital counting technology that directly measures the expression levels of a broad 
range of mRNA or miRNA without cDNA synthesis and amplification.122,123 It utilizes a pair of 
oligonucleotide probes, a capture probe and a reporter probe, that recognize and bind to the target 
genes (Figure 1.4). The reporter probes contain a barcode consisted of six fluorophores which can 
be four different colors. The biotin tag of the capture probe immobilizes the probe-gene complex 
on the slide coated with streptavidin through biotin-avidin binding, where the complexes are 
scanned by the fluorescent microscope. The genes are then quantified by directly counting the 
fluorescent barcodes, and therefore achieve absolute quantification without any amplification. The 
direct measurement prevents the bias induced by the amplification that is typically required for 
other PCR-based sequencing technologies. Therefore, NanoString can be a superior alternative for 
NGS to analyze low-abundance targets such as EV nucleic acid.  
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Figure 1.4 Principle of NanoString for nucleic acid quantification and profiling.  
(A) The nucleic acid suspension is mixed with the capture probe and reporter probe. (B) The 
capture probes and reporter probes bind to the targets and form probe-target complexes. (C) The 
complexes are immobilized on the streptavidin surface through biotin-avidin binding for 
quantification. Subsequently, fluorescent barcodes are counted, getting the number of the 





Over the past few decades, the field of EVs has been evolving rapidly. Significant efforts have 
been focused on investigating the role of EVs as mediators for disease progression and potential 
biomarkers. However, the study of EVs are still hampered by the lack of reliable and efficient 
methods for isolation and characterization. Microfluidic technologies have demonstrated great 
potential for isolating and characterizing EVs. Further studies and advancements of microfluidics 












Microfluidic Technologies for the Isolation and Characterization of 
Extracellular Vesicles and Evaluation of their Functional Role in 
Amyotrophic Lateral Sclerosis 
 
2.1    Abstract 
Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease characterized by 
motor neuron death and muscle atrophy. Clinical and molecular observations suggest that ALS 
proceeds in a patterned and prion-like manner, perhaps driven by extracellular vesicles (EVs). EVs 
harbor, transfer, and spread molecules associated with ALS pathogenesis such as misfolded SOD1 
and TDP-43 proteins as well as dysregulated microRNAs. However, the role of EVs cargo in ALS 
is still poorly understood. Immuno-affinity based microfluidic technologies have acquired special 
interest to concentrate and to isolate EVs. In this study, we investigated the EVs availability in 
ALS participants compared to healthy controls. Furthermore, we compared miRNA derived from 
EVs in frontal cortex, spinal cord and serum. We used an immuno-affinity-based microfluidic 
device, the ExoChip, for isolation and quantification of EVs. Furthermore, western blotting and 
electron microscopy were used for validation of vesicle isolation, and qPCR and NanoString 
profiling to evaluate EVs miRNA cargo.  The pathway analysis of predicted miRNA target genes 
was performed to identify pathways that are commonly dysregulated among the frontal cortex, 
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spinal cord and serum. We demonstrated that miRNA cargo of circulating EVs may mirror the 
central nervous system disease state in ALS; therefore, EV miRNAs are potential biomarkers of 
ALS. 
2.2    Introduction 
Amyotrophic lateral sclerosis (ALS) is a heterogeneous terminal neurodegenerative disorder.124-
127 Neurodegeneration and voluntary skeletal muscle atrophy proceeds in a systematic manner 
resulting in respiratory failure and death within 3-5 years after symptoms onset.128-130 The only 
interventions available for ALS include comprehensive patient care measures, Riluzole, and 
Edaravone.131,132 However, these approaches provide limited improvement in patient survival due 
to unknow disease etiology and the lack of sensitive biomarkers for diagnosis, prognosis, and 
disease progression.133   
Extracellular vesicles (EVs) are ubiquitously secreted membrane vesicles.1,2 EVs contain 
molecular cargo from the releasing cell, they travel in the circulating system, and they are stable 
in various types of biological fluids and tissues.134,135 In the nervous system, EVs may promote 
neurodegeneration by transporting and delivering aberrant molecules between neuronal and non-
neuronal cells in a systematic and prion-like manner; therefore “spreading” the disease.70,136-138 
These tiny vesicles mediate cell function by carrying molecular machinery able change recipient 
cells behavior.6,135 Genetic molecules, proteins, and metabolites are packaged in these vesicles and 
changes in their abundance are associated with health and disease in response to extracellular 
stimuli .6,139,140  
Importantly, the cargo shuttled via EVs in the central nervous system is able to cross the blood-
brain barrier; therefore, EVs and their cargo are attractive biomarker candidates for neurological 
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diseases.141,142 Mobility, molecular mechanisms of action, and diagnostic implications of EVs and 
their cargo are not well understood in ALS. MicroRNAs (miRNAs) packaged in EVs have 
emerged as important biomarkers and pathophysiological candidates for neurodegeneration.53,67,143 
miRNAs are small noncoding RNAs that regulate gene expression post-transcriptionally by 
targeting and destabilizing multiple mRNAs; therefore, regulating physiological and pathological 
processes.132,144-146 Dysregulated miRNAs levels in ALS biofluids and postmortem tissue suggest 
they have an important function in disease pathology.147,148  
Microfluidic immunoaffinity technology has recently been developed to capture highly pure EVs 
using small amounts of bio-samples. This methodology utilizes an antibody that recognizes surface 
antigens on EVs to quickly and selectively isolate them from other sample components84,90. In this 
study, we optimized an immuno-affinity-based microfluidic device, the ExoChip89 to isolate, 
characterize, and quantitate EVs and their miRNA cargo from ALS and control blood and frozen 
postmortem tissue. Our results indicate that miRNA cargo from circulating EVs reflect 
pathological signatures from diseased tissue.   
2.3    Methods 
2.3.1  Study participants and sample processing 
ALS participants were recruited at the University of Michigan ALS clinic. The status of the ALS 
participants was determined by an ALS neurologist applying the revised EI Escorial Word 
Federation of Neurology criteria,149 electromyography (EMG), and clinical and family history data. 
Age and sex-matched control participants. Control subjects were eligible to participate if (1) they 
did not have a diagnosis of ALS or other neurodegenerative condition, and (2) did not have family 
history of ALS in a first or second-degree blood relative. Participants older than 18 years of age 
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and/or next of kin provided informed consent. This research was approved by the University of 
Michigan Medical School Institutional Review Board.  
Whole blood samples were drawn and collected in EDTA tubes.  After centrifugation for 10 min 
at 2000 RCF, the top layer of plasma was collected. The plasma was mixed with an equal amount 
of Pacific Hemostasis Thromboplastin D (Thermo Scientific) and incubated at 37 °C for 15 min 
to coagulate plasma fibrinogen and clotting factors. The serum was obtained by collecting the 
supernatant and stored immediately at −80 °C. 
For brain and SC, approximately 100 mg of motor cortex and 300 mg of SC were used to make 
tissue homogenates as previously reported.150 Briefly, tissue was homogenized in 1ml of 1x PBS 
pH 7.4 supplemented with protease inhibitors (Roche Diagnostics, Mannheim, Germany; 1 
tablet/10ml buffer) using a glass homogenizer (company). The tissue was sheered using a 26.5 
gouge syringe and the homogenate was centrifuged at 300g for 10 min (max speed in 
microcentrifuge at 4 °C). The supernatant was filtered through a 0.2 um syringe filter (Millipore, 
Carrigtowhill, Cork, Ireland). A 1:10 dilution was used to determine protein concentration using 
BCA kit (Pierce/ThermoFisher, Waltham, MA USA).  
2.3.2  Fabrication of SU-8 mold for the Exochip device 
The mold for the polydimethylsiloxane (PDMS) device is formed from a negative photoresist SU-
8 100 patterned silicon wafer using standard soft lithography techniques. SU-8 100 (Microchem. 
Corp., Newton, MA) was spin coated onto the silicon wafer at 2300 rpm for 60 seconds. This was 
followed by soft baking at 65 °C for 10 min and at 95 °C for 70 min. After UV exposure of the 
pattern onto the wafer for 12 sec using MA-6 aligner, the wafer was baked at 65 °C for 3 min and 
95 °C for 10 min. The wafer was subsequently developed and rinsed with IPA to remove the 
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inactivated photoresist. The wafer was then hard baked for 3 min at 150°C. A post height of 50 
μm was achieved. 
2.3.3  Device fabrication and functionalization 
The flow chamber of the chip was made from PDMS. Well-mixed PDMS and curing agent (10:1 
ratio) were poured onto a SU-8 mold. The mold was then placed in a desiccator to remove bubbles. 
The polymer was solidified at 65 °C overnight in the oven. After baking, the polymer was peeled 
off from the mold and punched with tissue core for tubing. The PDMS chamber was bonded to a 
standard sized glass slide via plasma surface activation of oxygen. The device was immediately 
injected and incubated with 3-mercaptopropyltrimethoxysilane (Gelest) to make the surface 
hydrophilic. NeutrAvidin was conjugated to the chamber using the crosslinking agent GMBS 
(Pierce). The device was functionalized with the capture antibody immediately before capture by 
adding a biotinylated anti-CD63 (Ancell) the NeutrAvidin through biotin-avidin chemistry.  
2.3.4  EV capture and on-chip quantification 
EV isolation was based on the immuno-affinity approach reported by Kanwar et al in 2014. The 
functionalized devices was injected with biotinylated anti-CD63 solution in TBS containing 1% 
(w/ v) BSA to react with NeutrAvidin at room temperature for 1 hr. The devices were then blocked 
with 3% BSA-TBS solution infused at a flow rate of 50 μl/min for 10 min and then incubated for 
20 min. Serum or homogenate of brain and SC samples (300~350 μl) derived from healthy 
volunteers or ALS patients were infused through the device at a flow rate of 6μl/min followed by 
a TBS rinse at a flow rate of 50 μL/min for 20 min. The device-immobilized EVs were stained 
with membrane dye for on-chip quantification or fixed for scanning electron microscope (SEM) 
or lysed for miRNA and protein extraction. 
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To label the captured EVs, the chambers were then flushed with fluorescent carbocyanine dye 
Vybrant™ DiO (Molecular Probes) at a flowrate of 20 μl/min for 10 min followed by incubation 
at 37 °C for 20 minutes for the DiO to stain the membrane of the EVs. Using BioTek-Synergy Neo 
multi-purpose plate reader, the fluorescent intensity can be measured at excitation wavelengths of 
485 nm and emission wavelengths of 510 nm. The fluorescent intensities measured were 
normalized with the fluorescence intensity of background signals. 
2.3.5  Scanning electron microscope (SEM) analysis of ExoChip captured EVs 
EV immobilized within the device were fixed in 2% paraformaldehyde (PFA) in PBS for 20 min 
and then rinsed for 20 min with TBS. The samples were dehydrated in series of ethanol 
concentrations in distilled water (30%, 50%, 70%, 95%, and 100%) for 10 min at each step. For 
hexamethyldisilazane (HMDS) dry, the samples were immersed for 10 min in solution of 1:1 
ethanol: HMDS and then transferred to 100% HMDS, followed by overnight air dry in the hood. 
The samples were then coated with gold by sputtering or carbon by thermal evaporation before 
imaging by FEI Nova 200 Nanolab Dualbeam FIB scanning electron microscope under low beam 
energies (2.0-5.0 kV) at the Electron Microscopy Analysis Lab (MC2) at University of Michigan. 
2.3.6  EVs size analysis 
SEM micrographs were used to analyze EVs size.   Image analysis was done using Metamorph 
(version 7.7.7. 0 Sab Jose, CA). Briefly, the threshold feature was used to identify EVs.  After all 
objects were isolated, objects were verified using a filter for total area of EV and shape factor (0 
indicates a straight line and 1 indicated a perfect circle).  Objects smaller than 2000 nm2 and with 
a shape factor smaller than 0.2 were discarded from the data set. Filtered data for total object area 
and shaper factor was logged in to excel and graphed. A linear mixed effect model with a random 
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patient intercept was used to take into account the correlated nature of the EV measurement (size) 
within patient. We evaluated difference in EV size between ALS and control patients using a 
likelihood ratio test. 
2.3.7  Western blotting 
To lyse the membrane of captured EVs, the chambers were flushed with radioimmunoprecipitation 
assay buffer (Sigma) at a flowrate of 20 μl/min and the protein will be collected from the outlet.  
The protein lysates were mixed with Laemmli sample buffer (Bio-Rad) and then heated at 95 °C 
for 3 min before separated by SDS-PAGE. The proteins were then transferred to the polyvinylidene 
difluoride (PVDF) membrane (Bio-Rad). The membranes were blocked with 5% milk/5% BSA in 
Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 hr at room temperature and then 
rinsed with TBST before incubated with primary antibodies diluted in TBST supplemented with 
3% BSA.  Subsequently, the membranes were washed with TBST and then incubated for 90 min 
with appropriate secondary antibodies diluted 1: 2000 with blocking buffer, as described above. 
After washing, the proteins were visualized using chemiluminescence and colorimetric detection 
kits (Bio-Rad). 
2.3.8  RNA extraction and Nanostring miRNAs analysis 
Total RNA from EVs was extracted from the device using Qiazol (QIAGEN). Qiazol eluted 
samples were vortexed for 15 min and incubated at room temperature for 5 min followed by the 
addition of chloroform (1/5 of Qiazol volume), vortexed for 15 sec, and incubated at room 
temperature for 3 min. The samples were centrifuged at 12k rpm for 15 min at 4 °C. RNA isolation 
was performed using Norgen columns (Norgen Biotek Corp., Thorold, ON, Canada) as indicated 
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by the manufacturer. The samples were eluted in 50 μl of DNAse and RNAse-free water and stored 
at -80 °C.  
2.3.9  miRNA expression profiling and data analysis 
EVs-contained miRNAs were profiled with the NanoString nCounter® Human v3 miRNA 
Expression Assay Kit (NanoString, Seattle, WA, USA) at the Genomics Shared Resource-
Comprehensive Cancer Center at Ohio State University.151 Each sample was scanned by the 
nCounter Digital Analyzer (NanoString) and expression data were extracted using the nCounter 
RCC Collector (NanoString).  
For data analysis, overall quality of the expression data was assessed using nSolverTM Analysis 
Software v3.1 (NanoString) according to manufacturer’s instruction. We performed principal 
component analysis (PCA) to visualize overall variation across samples. Then, two different 
software packages were used for DEmiRNA analysis: nSolver v3.1 from NanoString and 
NanoStringDiff, an R package specifically designed for NanoString nCounter data.152 For nSolver 
analysis, nCounter data were normalized to the top 100 most highly expressed miRNAs and 
differential expression of miRNAs were examined using nSolver’s differential expression testing 
menu between groups. Ratios of miRNAs between groups and statistical significance values (p-
value) as well as False Discovery Rates (FDRs) were obtained. In the NanoStringDiff analysis, 
normalization of the data was done using positive controls, negative controls, and housekeeping 
genes embedded in the nCounter system. Differential analysis was also performed using 
NanoStringDiff and log fold-changes and multiple testing adjusted statistical significance values 
(q-value) were obtained. The significance cutoff for differential expression was FDR or q-value < 
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0.05. The dysregulated miRNAs identified by both nSolver and NanoStringDiff were deemed as 
DEmiRNAs in this study. 
2.3.10  Pathway analysis 
DIANA-miRPath v3.0 was employed to characterize the biological functions and pathways of the 
DEmiRNAs focusing on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.153 
KEGG pathways with FDR < 0.05 were determined to be significantly enriched among the 
DEmiRNAs from each tissue type (frontal cortex, spinal cord, and serum). To identify the overall 
theme of these enriched pathways, concept-similarity networks were generated based on their gene 
contents in these pathways using RichR, our in-house analysis R package 
(https://github.com/hurlab/RichR). 
2.3.11  Statistical analyses 
Fisher's exact test and student’s t-test were used to determine demographic differences between 
cases and controls. Statistical analyses were done in GraphPad Prism v7 (GraphPad Software, La 
Jolla, CA, USA). Significance was defined as P < 0.05. 
2.4 Results 
2.4.1  Participants and samples 
Frontal cortex (FC), spinal cord (SC), and serum were obtained from 15 ALS and 16 control 
participants (Table 2.1).  For 11 of the ALS participants, all three tissues were collected from the 
same subject. ALS onset segment was limb for fourteen participants (93.33%) and bulbar for 1 
participant (6.77%). In this study, we used a cohort of ALS subjects with no known familiar history 
of ALS or mutations in the SOD1 gene or aberrant expansions in the C9orf72 gene. Sex and age 
distribution were similar for ALS and control participants. All ALS participants were Caucasian, 
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while the control group consisted of fifteen Caucasian (93.75%) and 1 Back/African American 
(6.25%).    
Table 2.1 Clinical characteristic of study participants 




Age (years)(a,b)   71.0, 64.4 ± 2.649, (47-80) 
60, 66 ± 2.954, (49-
85) 
0.726# 
Sex Male 8 (53.33%) 9 (56.25%) >0.99¶ 
  Female 7 (46.67%) 7 (43.75%)   
Onset Bulbar 1 (6.67%) -   
  Limb 14 (93.33%) -   
PMI (b)*   13.73±2.11 h (n=11) -   
Ethnicity Caucasian 15 (100%) 15 (93.75)   
  Black/AA - 1 (6.25%)   
(a) median; (b) mean ± standard error; (range); PMI, Postmortem Interval; *For autopsy tissue, no data available from one 
subject; AA, African American; #Student t-test, ¶Fisher's exact test 
  
 
2.4.2  Characterization of EVs captured by the ExoChip 
The ExoChip integrates microfluidic technology and an immuno-affinity approach to isolate and 
characterize EVs. We previously demonstrated that the ExoChip is able to capture EVs from 
serum.89 In this study, we refined the devise to compare EVs and their cargo from postmortem 
frozen FC, SC, and serum (Figure 2.1). Vesicle size and morphology of ExoChip captured EVs 
were assessed using scanning electron microscopy (SEM). EVs displaying typical spherical shape 
were observed with the anti-CD63 coated ExoChip, but not with the uncoated or PBS control; 
suggesting vesicle capture is specific (Figure 2.2A). The overall size of the captured vesicles from 
FC, SC, and serum ranged from 5.64 nm to 636.03 nm (213.78 ± 84.91 SD nm) in diameter. 
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Immunoblot analysis indicated that of ExoChip-captured EVs were positive for the EV marker 




Figure 2.1 Workflow.  
Extracellular vesicles (EVs) immobilization and characterization. EVs from FC, SC and serum 
from healthy or ALS subjects are captured by a CD63-antibody coated ExoChip. To quantify the 
captured EVs, the chip is processed with lipophilic (DiO) staining, and then measure the levels of 
fluorescently stained EVs by fluorescence intensity analysis. Immobilized EVs were analyzed by 
western blotting and EV cargo by NanoString. 
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2.4.3 EVs size and availability in sporadic ALS 
We compared the EVs size from ALS and controls from frontal cortex, spinal cord and serum. The 
mean dimeter of EVs for FC was 255.07 ± 5.25 SEM nm for ALS and 245.86 ± 4.45 SEM nm for 
control; for SC, 193.92 ± 3.42SEM nm for ALS and 141.94 ± 2.59 SD nm for control and for serum, 
187.12± 2.74 SEM nm for ALS and 247.33 ± 2.96 SEM nm for control (Figure 2.2B). Using a 
linear mixed model, we found significantly larger EVs in SC for ALS patients compared to control 
patients (P=0.03).  This trend was reversed for serum, in which the size of EVs in ALS was smaller 
than that of controls (P=0.02). Finally, we did not detect a significant difference in size of EVs 
between ALS patients and controls in FC (P= 0.57).    
To determine the abundance of EVs in ALS, we measured membrane associated lipids in EVs by 
fluorescence intensity assays. We observed a slight but no significant difference in the amount of 
EVs between ALS and controls (Figure 2.2D) in all samples, suggesting that the overall levels of 
EVs are not viable as biomarker for ALS.  
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Figure 2.2 Characterization ExoChip captured EVs from frontal cortex (FC), spinal cord 
(SC), and serum of ALS and control (Cntl) subjects.  
(A) Scanning electron micrograms (bars = 1 m).  (B) Size profile and frequency (%) by size (nm) 
of EVs measured with SEM images in (A).  ALS (black) and healthy controls (grey). (C) Protein 
characterization of ExoChip captured EVs from FC, SC, and serum using anti-CD9 antibody. (D) 
On-chip immobilized and purified EVs were labeled with a fluorescent lipophilic dye (DiO). The 
fluorescent intensity values obtained from the chip corresponding to healthy Cntls and cases were 
normalized against the background signal from the plate. Fold change is shown in a Min. to Max 
Wisker plot. FC (Cntl= 8, ALS=12), SC (Cntl= 6, ALS= 12), and Serum (Cntl= 9, ALS= 7).  
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2.4.4 EVs-contained miRNAs are dysregulated in ALS 
Mature miRNAs contained in EVs from frontal cortex, spinal cord, and serum captured by the 
ExoChip were profiled by NanoString, which uses the probes conjugated with fluorescent barcodes 
and single molecule imaging to directly count miRNA copies.154 Principal component analysis 
(PCA) indicates that EV-derived miRNAs from spinal cord and serum samples are clearly 
clustered by ALS or control, while frontal cortex EV-derived miRNAs are not (Figure. 2.3). 
 
Figure 2.3 Principal component analysis (PCA).  
The analysis was performed on EV miRNA data from spinal cord, frontal cortex and serum from 
ALS patients and healthy controls.  
Significantly differentially expressed miRNAs (DEmiRNAs, p<0.05) in ALS compared to controls 
for each tissue were identified using a stringent pipeline in which DEmiRNAs overlapped with 
two independent platforms, nSolver and NanoStringDiff 152 (Figure 2.4A).  
We observed an overall decrease in EV-derived miRNA levels in ALS frontal cortex and spinal 
cord compared to controls, while the opposite was observed for serum samples. In frontal cortex, 
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out of 11 dysregulated miRNAs, three of them show increased levels. In spinal cord, a total of 22 
miRNAs were dysregulated with respect to control. The levels of 4 miRNAs were higher while 18 
were lower in ALS. The opposite trend was observed in serum, where a total of 27 miRNAs had 
increased expression while 8 had decreased expression (Figure 2.4B-D). Five dysregulated 
miRNAs, miR-33b-5p, miR-122-5p, miR-664a-3p, miR-1268b, and miR-4286b, overlapped 
between serum and spinal cord; while only one miRNA, 185-5p was, dysregulated in both frontal 
cortex and spinal cord. Note that among all the 5 overlapped miRNAs, only miR-4286b is 
differentially expressed in the same direction in the tissues while the other four dysregulated in the 
opposite direction. We did not identify a common changing miRNA between the three tissues 




Figure 2.4 EV-contained miRNAs are dysregulated in frontal cortex, spinal cord, and 
serum in ALS.  
(A) Schematic analysis workflow of EVs-contained miRNAs. The miRNAs were profiled using 
NanoString and normalized by nSolver and NanoStringDiff. Differentially expressed miRNAs 
overlapping with both methods are shown as DEmiRNAs. EV-derived DEmiRNA from (B) SC 
(n=12 for ALS and n=6 for healthy control), (C) FC (n=12 for ALS and n=8 for healthy control), 
and (D) plasma (n=7 for ALS and n=9 for healthy control) are shown to increase (yellow) or 
decrease (orange). Fold change of significant (p<0.05) mature miRNAs was determined between 
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ALS and control groups and the value from nSolver is shown. (E) Venn diagram showing common 
dysregulated EVs-derived miRNAs from different tissues in ALS. 
2.4.5 Dysregulated EVs-contained miRNA in ALS. 
To better understand the role of dysregulated EV-contained miRNAs in ALS pathology, we 
examined DEmiRNA predicted targets and their corresponding functional KEGG pathways for 
each tissue using DIANA-mirPath analysis.153 A total of 81 KEGG pathways were significantly 
enriched (FDR<0.05). Of those pathways, 19 overlapped among all three tissues including “Axon 
guidance”, Glutamatergic synapse”, “GABAergic synapse”, cAMP signaling”, Oxytocin 
signaling”, “Endocytosis”, and cancer associated pathways (Table 2.2).  
Table 2.2 KEGG pathway analysis for the predicted miRNA targets. 
KEGG pathways 
FC SC Serum Overlap 
-log10 p-value   







Wnt signaling pathway 6.2 2.4 2.0 
Signaling pathways regulating pluripotency of 
stem cells 5.7 5.1 1.7 
Hippo signaling pathway 5.4 5.1 4.8 
TGF-beta signaling pathway 4.6 2.5 2.0 
ErbB signaling pathway 4.5 1.6 4.7 
Axon guidance 4.4 5.4 4.6 
Oxytocin signaling pathway 4.2 1.4 1.6 
Endocytosis 3.0 1.5 3.1 
Glutamatergic synapse 2.9 2.6 2.7 
Adrenergic signaling in cardiomyocytes 2.4 1.5 3.5 
FoxO signaling pathway 2.3 4.0 1.6 
Retrograde endocannabinoid signaling 2.0 1.7 3.4 
Circadian entrainment 1.7 1.4 2.9 
Focal adhesion 1.7 1.5 1.4 
Nicotine addiction 1.5 2.0 1.6 
Morphine addiction 1.4 3.6 6.7 
GABAergic synapse 1.4 2.7 4.6 
cAMP signaling pathway 1.4 2.6 2.8 
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N-Glycan biosynthesis   1.3 2.3 
Insulin secretion   1.5 1.9 
cGMP-PKG signaling pathway   4.1 1.8 
Transcriptional misregulation in cancer   3.1 1.6 
Neurotrophin signaling pathway   1.7 1.6 
Gap junction   1.9 1.5 
Prion diseases 7.5 5.3   
Thyroid hormone signaling pathway 5.4 5.3   
Pathways in cancer 5.4 3.5   
Adherens junction 5.4 2.2   
Glioma 5.4   1.8 
Ubiquitin mediated proteolysis 4.3 3.6   
Circadian rhythm 4.1 1.4   
AMPK signaling pathway 2.6   1.4 
Regulation of actin cytoskeleton 2.4 1.5   
Biotin metabolism 2.3 1.7   
Renal cell carcinoma 2.3 4.6   
Ras signaling pathway 2.2 1.5   
mTOR signaling pathway 2.1 1.7   
Bacterial invasion of epithelial cells 2.1 1.5   
Prostate cancer 1.9 2.2   
Insulin signaling pathway 1.9   1.5 
Sphingolipid signaling pathway 1.9   2.1 
Lysine degradation 1.8   3.1 
Dorso-ventral axis formation 1.7 1.9   
MAPK signaling pathway 1.7 1.5   
Amphetamine addiction 1.6   2.5 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 1.6 3.3   
Dopaminergic synapse 1.5   1.5 
Endocrine and other factor-regulated calcium 







Glycosphingolipid biosynthesis - lacto and 
neolacto series   2.1   
mRNA surveillance pathway   1.7   
Aldosterone-regulated sodium reabsorption   1.6   
Rap1 signaling pathway   1.6   
Gastric acid secretion   1.5   
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Long-term potentiation   1.5   
Inositol phosphate metabolism   1.5   
Colorectal cancer   1.4   
Mucin type O-Glycan biosynthesis     13.7 
Cell adhesion molecules (CAMs)     3.1 
Estrogen signaling pathway     3.0 
Calcium signaling pathway     2.9 
Cholinergic synapse     1.8 
Other types of O-glycan biosynthesis     1.8 
PI3K-Akt signaling pathway     1.4 
Amoebiasis     1.3 
Pancreatic cancer 4.3     
Oocyte meiosis 3.5     
Long-term depression 2.8     
Type II diabetes mellitus 2.3     
Melanoma 2.3     
Chronic myeloid leukemia 2.1     
Shigellosis 2.1     
GnRH signaling pathway 2.1     
Hedgehog signaling pathway 1.7     
Non-small cell lung cancer 1.6     
HIF-1 signaling pathway 1.6     
p53 signaling pathway 1.5     
Choline metabolism in cancer 1.5     
Hepatitis B 1.4     
Small cell lung cancer 1.4     
 
The inter-relationship among the identified pathways was visualized with Cytoscape155 and the 
genes involved in these pathways were also predicted.  The connection between the nodes (edges) 
denotes the degree of shared genes between the two pathways, and six densely connected clusters 





Figure 2.5 Association network of pathways in sALS human FC, SC, and serum.  
Squares correspond to pathways identified in all three tissues, diamonds to pathways identified in 
either two types of the three tissues, and circles to pathways identified in just one type of tissue. 
The size of the nodes denotes the number of miRNAs in that pathway while the color gradient 
represents -log p-value (see color scale). Pastel colors delimit highly connected pathways clustered 
by MCODE Cytoscape156 (Top panel). Non-clustered pathways are arranged by tissue (bottom 
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2.5  Discussion  
The lack of biomarkers limits early detection and effective treatment development for ALS. In the 
current study, we used microfluidic technology to determine whether circulating EVs availability 
and their cargo reflect pathological signatures from diseased tissue. Our approach provides an 
efficient, quick, and inexpensive alternative to extract and quantify EVs and their cargo from serum 
and postmortem tissues. We identified vesicle size differences and several dysregulated EV-
contained miRNAs in frontal cortex, spinal cord, and serum associated with biological pathways 
related to neurodegeneration.  
Availability of EVs and their cargo depend on the health and pathological state of the cell, thus 
serving as potential biomarkers to monitor disease progression and treatment outcome.141,157 35,158 
We did not observe significant difference in EVs abundance between ALS and control samples, 
regardless of tissue type. In parallel to reports in Parkinson’s disease159, our data suggest that EVs 
levels are not biomarker for neurodegenerative disease, contrasting with studies in cancer.160 
However, EVs concentration is influenced by many factors including age, sex, time of sample 
collection, and EV phenotype.161,162 Although our case cohort was composed of only sporadic ALS 
patients, other clinical subgroups that define ALS patients, such as family history of 
neurodegeneration, site of onset, progression of the disease, age, and gender, may need to be taken 
in consideration in a larger cohort to detect significant altered levels of EVs in ALS. Notably, we 
observed EVs size difference between cases and controls in spinal cord and serum. EV size may 
define vesicle kind as well as content in disease. 
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EVs-contained miRNAs traveling from disease neuronal tissue to the blood stream may facilitate 
the identification of pathological events.163-165 Dysregulated miRNAs are potential diagnostic and 
prognostic biomarkers for neurodegenerative diseases including ALS.166 We identified common 
and unique EVs-contained dysregulated miRNAs form circulating and disease tissue, some of 
which are associated with distinct ALS pathology. For instance, miR-132-3p is decreased in sALS 
serum and patient-derived lymphocytes derived from patients with TDP-43 but not from 
lymphoblastoid cells with SOD1 mutations; This suggested the potential of miRNAs not only as 
markers for ALS in general but as an indicator for different forms of ALS.167  
Among the 50 dysregulated EV-contained miRNAs identified, six overlapped between neuronal 
and blood tissues and they are associated with neuron survival and degeneration. For example, 
miR-122 inhibits neuronal cell death in ischemic stroke and together with miR-33, these miRNAs 
are important regulators of lipid metabolism.168,169 ALS patients show a defined switch from 
glucose to lipid metabolism resulting in elevated lipid usage as energy fuel in neurons and 
increased oxidative stress, a pathological marker of ALS.170 miR-185 protects against autophagy 
and apoptosis in cellular models of Parkinson’s disease and it modulates DNA Methyltransferase 
1 (DNMT1), therefore regulating global methylation, which is altered in ALS.171-173  
Notably, only one of these EV-contained miRNAs was dysregulated in the same direction 
(upregulated). Opposite EV-miRNAs dysregulated direction is observed in breast cancer tumor 
tissue and plasma.174 Whether this reflects EVs-contained miRNAs retention in disease tissues in 
such a way that the opposite result is observed in cargo from circulating EVs, needs to be 
determined. Although we did not observe high overlap between individual dysregulated miRNAs 
with FC, SC and serum, we identified pathways regulated by EV-contained DEmiRNA shared by 
the tissues. Many of the identified pathways are known to be associated with ALS pathology and 
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neuron degeneration. For instance, some of the shared identified pathways are related to metabolic 
dysfunction, including fatty acid oxidation and AMPK signaling pathways, which is consistent 
with hypermetabolism and hyperlipidemia observed in ALS patients.175  Moreover, we identified 
EVs-contained dysregulated miRNAs highly enriched in pathways associated to 
neurodegeneration such as GABAergic synapse system and the Wingless-related integration site 
(Wnt)  signaling pathway.176-178 Alterations of the Wnt signaling pathway in neuronal and 
supporting cells contribute to motor neuron degeneration in ALS.179,180 In addition,  the 
transforming growth factor β (TGF- β), the core module of TGF- β signaling pathway, regulates 
motor neuron survival by modulating neuroinflammation and fibrosis.181,182  Axon guidance plays 
essential roles in development of synaptic connections, thus dysregulation of axon guidance 
proteins such as Neuropilin and Semaphorin is observed in neurodegeneration.183,184  
Notably, we identified a cluster of carcinogenesis pathways, such as prostate, melanoma, and brain 
cancer.  These data parallel recent reports associating neurodegeneration and cancer. Depending 
on the cancer type, cancer patients present either higher or lower risk for neurodegenerative 
diseases.185,186  Prostate cancer is inversely correlated to ALS onset, while the opposite trend is 
observed for melanoma and tongue cancers.185,187 The Hippo signaling pathway is commonly 
recognized as a tumor suppressor pathway.188,189 The mammalian sterile 20 (STE20)-like kinase 1 
(MST1), one of the key components of this pathway is elevated in a mouse model of ALS and 
promotes motor neuron death.190,191 Furthermore, we found that the mitogen-activated protein 
kinases (MAPK1) was the most common predicted target of EV-contained DEmiRNAs between 
the three different tissues. Dysregulation of the MAPK signaling pathway promotes drug resistance 
in cancer and leads to abnormal accumulations of neurofilaments in ALS.192,193 Alteration of EV-
contained miRNAs in cancer and ALS may regulate common biological mechanisms and signaling 
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pathways that control cell death and survival.  In some cases, in a protective fashion, while in 
others with detrimental consequences. 
2.6 Conclusion 
The ability of EVs to ubiquitously carry molecular information from one cell to another provides 
an opportunity to assess proteomic and genetic information about neurodegenerative disease 
diagnostics.194 The involvement of EVs in the progress of ALS is poorly understood. Our study 
implicates the role of EVs in ALS by identifying alterations of EV size and miRNA cargo in FC, 
SC, and serum. Using microfluidic technology, we identified EV miRNAs involved in biological 
pathways across tissues. These miRNAs may be potential biomarkers for screening onset or 











Microfluidic Device for High-Throughput Affinity-Based Isolation 
of Extracellular Vesicles 
 
3.1 Abstract 
Immunoaffinity based EV isolation technologies use antibodies targeting surface markers on EVs 
to provide higher isolation specificity and purity compared to existing approaches. One standing 
challenge for researchers is how to release captured EVs from the substrate to increase downstream 
and biological studies. The strong binding between the antibody and antigen or the antibody and 
substrate is commonly unbreakable without operating at conditions outside of the critical 
physiological range, making the release of EVs problematic. Additionally, immuno-affinity 
approaches are usually low-throughput due to their low flow velocity to ensure adequate time for 
antibody-antigen binding.   To overcome these limitations, we modified the Oncobean chip, a 
previously reported circulating tumor cell isolation microfluidic device. The Oncobean chip is a 
radial flow microfluidic device with bean-shape microposts functionalized with biotin-conjugated 
EPCAM antibody through biotin-avidin link chemistry. It was demonstrated that the high surface 
area and varying shear rate provided by the bean-shaped posts and the radial flow design in the 
chip, enabled efficient capture of CTCs at high flow rate.  We replace the anti-EPCAM with 
antibodies that recognize common EV surface markers to achieve high-throughput EV isolation. 
Moreover, by incorporating desthiobiotin-conjugated antibodies, EVs can be released from the 
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device after capture, which offers a significant improvement over the existing isolation. The 
released EVs were found to be functional by confirming their uptake by cells using flow cytometry 
and fluorescent microscopy.  We believe the proposed technology can facilitate the both the study 
of EVs as cell-to-cell communicators and the further identification of EV markers. 
3.2 Introduction 
Extracellular vesicles (EVs) are a group of heterogeneous membrane-bound vesicles that include 
exosomes, microvesicles and apoptotic bodies, which are actively secreted by almost all cell types 
into extracellular spaces.1,195 These vesicles have been widely investigated and are considered to 
be powerful mediators of cell-to-cell communications.  They can travel across great distances 
within the human body through the circulation and release their cargos upon internalization by  
recipient cells.2  Emerging evidence has shown that genetic information carried by these 
nanovesicles supports various biological functions such as activating anti-apoptosis, enhancing 
blood vessel formation and regulating immune response, to name a few.2,134,196,197 Moreover, they 
have been shown to carry and transfer proteins and nucleic acids that are reflective of their 
originated cells.  
The role of EVs and their cargo in promoting pathological processes in various kinds of disease, 
such as cancer and neurodegenerative diseases is becoming clearer, with many studies linking 
specific EV cargo to disease progression and outlook.19,158,198,199 As such, proteomic and genomic 
analysis of EVs can potentially provide a valuable biomarker for the detection, characterization, 
and monitoring of disease progression. For instance, miRNA dysregulation in EVs have been 
detected in various types of cancer, such as brain and lung cancer.42,200,201 The miRNAs carried by 
EVs released from the tumor or the tumor microenvironment have been shown to deeply influence 
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tumorigenesis and therapeutic response.21,200 For example, miRNAs found in EVs secreted by lung 
cancer cells were shown to be promote tumor growth and metastasis through alternation of the 
immune response.202 Furthermore, dysregulated miRNAs in EVs have also been considered as a 
diagnostic tool for many cancer types.203,204 In addition to cancers, recent studies have shown that 
the cargos shuttled by EVs can be biomarkers for neurodegenerative disease, such as Alzheimer’s 
and Parkinson's disease.205,206 Thus, isolating and analyzing the contents of EVs can provide 
researchers and clinicians valuable information about a patient’s diseases status, potentially even 
informing future diagnostic or prognostic tests.  
Despite the valuable information housed in EVs, the lack of efficient isolation methods is still a 
major limitation for the study of EVs. The extremely small and heterogeneous size of EVs within 
a sample, 30-2000 nm, makes isolation technically challenge. The current standard isolation 
method is differential ultracentrifugation (UC), which is used to isolate EVs from various sample 
types including cell culture supernatant, blood, urine, and cerebral fluid.76,207,208   Using UC, 
samples are processed through serial centrifugation steps with  increasing speeds to remove cells 
and cellular debris and eventually pelleting the target population of vesicles. Sucrose density 
gradients are often utilized in combination with UC to further deplete any extracellular proteins, 
achieving better separation and purity.  However, critical drawbacks such as lengthy processing 
time and inefficient yields make it challenging for EV studies where the sample volume is low or 
the target EVs are low in number.78,83 Furthermore, several studies have shown that the high 
centrifugation force damages the membrane integrity of EVs and promotes EV rupture and 
coagulation, hindering potential downstream analysis. In a push to move away from 
ultracentrifugation, the need to reduce EV loss, increase purity, and preserve sample integrity has 
led the development of new isolation technologies to replace ultracentrifugation.209 
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One of the most promising alternative EV isolation techniques, immunoaffinity-based capture 
technologies, use antibodies to target surface markers of EVs. Common targets of immunoaffinity 
based captured are a group of proteins called the tetraspanins, specifically CD9, CD63, and CD81, 
which are broadly accepted EV markers.91,209 For example, Koliha et al have demonstrated EV 
capture using magnetic beads coated with antibodies against EV markers, such as CD9, CD63, and 
CD81.210 Since the molecular composition of EVs is also dependent on their parent cells, different 
markers such as epithelial cellular adhesion molecule (EPCAM) and epidermal growth factor 
receptor (EGFR) have also been used for capturing specific EV populations. For instance, 
magnetic beads coated with chondroitin sulphate peptidoglycan 4 antibody has been reported to 
isolate EVs from plasma to study melanoma cancer.211  
Among the types of immunoaffinity isolation technologies, microfluidic platforms with antibody-
coated surfaces have become a promising alternative EV isolation strategy. These devices have 
very small dimensions, facilitating minimized reagent volumes, isolation time, and procedural 
costs while enhancing the product purity and sensitivity.83,90 For instance, Kanwar et al. developed 
a microfluidic platform, Exochip, that isolates EVs from plasma from pancreatic cancer patient 
using anti-CD63.89 The device enables rapid EV quantification and facilitates EV protein and 
miRNA characterizations.  Zhang et al. designed a device with graphene oxide nanoposts coated 
with CD81 antibody to detect and isolate EVs at low detection limit.92.Vaidyanathan et al. 
fabricated a microfluidic device with functionalized gold electrodes coated with CD9, human 
epidermal growth factor receptor 2 (HER2) and prostate specific antigen (PSA) antibodies.212 The 
capture of EVs is enhanced by nanoshearing between the electrodes induced by an alternating 
electric current. Zhang et al. devised a 3D-nanopatterned microfluidic chip with a porous 
herringbone mixer fabricated by assembled silica colloids to capture EVs from serum samples in 
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ovarian cancer.114  They have shown that their device is compatible with downstream analysis 
including ELISA, western blotting and digital PCR. Although current immunoaffinity isolation 
technologies provide more specific EV enrichment and isolation, these technologies suffer from 
limitations of low throughput since the high flow rates would hinder the antigen-antibody 
interaction. Additionally, surface-antibody-EV binding is tight, making it challenging to release 
and retrieve viable EVs post isolation. Being unable to recover intact EVs is a critical drawback 
for studying the interaction between cells and EVs, hindering both in-vitro and in-vivo studies. 
Therefore, despite advances in the field, a need exists to further improve microfluidics platforms 
to isolate and harvest EVs. 
Many immunoaffinity-based technologies for EV capture rely on the high-affinity binding of 
biotin-avidin to immobilize the capture antibodies on the micro/nano-structured surface or beads. 
Owing to the simple procedure and stable binding, biotin-conjugated antibodies have been used 
for antibody-based capture not just for EVs but also for other targets including cells, lipids, and 
enzymes.213,214 However, the irreversibility of the biotin-avidin binding limits the use of captured 
EVs as the EVs would need to be lysed in some way for removal. Strategies to break biotin-avidin 
binding frequently operate at conditions outside of the physiological range, including extreme pH 
and high temperatures, which potentially reduce the integrity of the captured samples.215,216  
The use of desthiobiotin, an analogue of biotin, has been reported to be an effective alternative to 
standard biotin.215 Desthiobiotin has a lower binding affinity to avidin than regular biotin, meaning 
that samples captured by desthiobiotin-conjugated antibodies can be eluted from an avidin-coated 
surface using a biotin solution. This elution leads to the replacement of desthiobiotin with biotin, 
effectively releasing the sample from the capture surface and allowing for downstream 
applications.101 This capture-release method has been used for the isolation and release cells and 
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proteins.217 In the present study, we incorporated this desthiobiotin release method to achieve the 
release of intact EVs using a high throughput immunoaffinity based microfluidic device. 
We have previously described the Oncobean chip, a radial flow microfluidic device with bean-
shape microposts functionalized with biotin-conjugated anti-epithelial cell adhesion molecule 
(EpCAM) antibody through biotin-avidin link chemistry.218 It was demonstrated that the high 
surface area and stable shear rate provided by the bean-shaped posts, as well as the radial flow 
design in the chip, enabled efficient capture of circulating tumor cells (CTCs) at high flow 
rates.218,219 Here, we apply this chip with antibodies against common EV surface markers, CD9, 
CD63, and CD81, to achieve high throughput EV isolation. Our results showed that the device is 
well suited to process large volumes of samples, which is ideal for obtaining high concentrations 
of EVs for downstream analysis. Furthermore, by using desthiobiotin-conjugated antibodies 
instead of biotinylated ones, EVs can be released and harvested from the device after capture. The 
released EVs were shown to be functional by demonstrating their internalization by cells based on 
flow cytometry. One exciting application of releasing exosomes is to investigate the uptake of 
exosomes into distant cells.  We performed initial experiments to first test the integrity of the EVs 
following release.  To do so we performed immunofluorescent labeling of EVs for common EV 
proteins (CD81 and CD63) before demonstrating successful staining using flow cytometry.  We 
then used fluorescently dyed EVs to perform an initial uptake experiment and demonstrated the 
uptake of released EVs by cells. We believe that this novel strategy can be used for high volume 
processing of samples for EV enrichment which will enable both systematic analysis of EV cargo 




3.3.1 Oncobean fabrication and functionalization 
The OncoBean Chip, a previously reported microfluidic device for isolating circulating tumor 
cells, was utilized for EV capture in the present study.218 The device is made of a 
polydimethylsiloxane (PDMS) top bonded to a glass slide. The mold for the 
polydimethylsiloxane (PDMS) device is fabricated using a negative photoresist, SU-8 100, 
patterned silicon wafer using standard soft lithography techniques. Briefly, negative photoresist 
SU-8 100 (MicroChem Corp) was spin coated onto a silicon wafer at 2350 rpm before performing 
UV exposure, post exposure baking, developing, and feature measuring.  Well-mixed PDMS and 
curing agent were poured onto a SU-8 mold at a ratio of 10:1 and degassed in a desiccator for 30 
minutes to remove all bubbles. The polymer was cured at 65 °C overnight in the oven. After 
baking, the polymer was peeled off from the mold and cut for surface functionalization. The 
PDMS chamber was bonded to a standard sized glass slide via plasma surface activation of 
oxygen.  
The completed device was processed with 3-mercaptopropyltrimethoxysilane (Gelest) in ethanol 
by syringe injection and incubated for an hour. This device was then washed with ethanol and 
treated with N-gamma-Maleimidobutyryloxy-Succinimide (GMBS) (ThermoScientific) for 30 
min.  This was followed by rinsing with ethanol and adding NeutrAvidin before incubating. The 




3.3.2 Sample preparation and EV isolation 
Whole blood samples from healthy donors were drawn into EDTA tubes and were subsequently 
centrifuged at 2000 x g for 15 minutes to collect the top layer of plasma. The isolated plasma 
samples were kept at -80 °C until use.  
3.3.3 Cell culture 
Patu8988t pancreatic cancer cell line was cultured in DMEM medium with 10% FBS. Cultures 
were incubated at 37 °C in a humidified 5% CO2 incubator (Thermo Fisher Scientific, Waltham, 
MA). Cells were grown until they reached 70–80% confluence, at which time, they were 
subjected to experimentation. 
3.3.4 EV capture and release 
Before experiments, the device was functionalized with the capture antibody by injecting biotin 
or desthio-biotin conjugated antibody in 1% bovine serum albumin (BSA) (Sigma Aldrich) in 
phosphate buffered saline (PBS) and incubating for 60 minutes.  After antibody immobilization 
and washing with 1mL of PBS at a flowrate of 50 μl/min, 3% BSA was processed at a flow rate 
of 50 μl/min for 10 min to block the excess reaction sites and prevent non-specific binding. 
Human plasma or cell culture medium were processed through the OncoBean Chip for EV 
capture, followed by washing with PBS at a flow rate of 50 μl/min for 20 min. The EVs captured 
by the desthiobiotin antiCD63 conjugated device were released from the device using a 0.5 mM 
biotin solution. The biotin solution was incubated for 1 hour in the device, followed by a wash 
with biotin solution and the collection of released EVs. The released EVs were either 
characterized by nanoparticle tracking analysis, NTA, using the NanoSight NS300 (Malvern 
Instruments, UK) to determine the size and concentrations, or proceeded to functional studies. 
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The EVs immobilized by the device using biotinylated antibodies were lysed for RNA and protein 
extraction. 
3.3.5 Electron microscope (EM) analysis of captured EVs 
A small portion of the PDMS top of the device after EV isolation was cut out using a biopsy punch.  
Each punched PDMS specimen was fixed in 2.5% glutaraldehyde in PBS at room temperature for 
one hour and then rinsed with PBS, followed by sequential dehydration with ethanol at 
concentrations of 50%, 70%, 90%, 95%, and 100% for 10 min each. The specimen was then 
immersed for 10 min in solution of 1:1 ethanol: hexamethyldisilazane (HMDS) and then 
transferred to 100% HMDS, followed by overnight air drying in the hood.  The dehydrated 
specimen was then attached to carbon double sided tape and was mounted on a SEM stub before 
coating using gold sputtering.  The EVs were examined by FEI Nova 200 Nanolab Dualbeam FIB 
scanning electron microscope under low beam energies (2.0-5.0 kV) at the Michigan Center for 
Materials Characterization (MC2) at University of Michigan. 
3.3.6 Western blotting and protein quantification 
To harvest the protein of the EVs captured, the device chamber was injected with RIPA buffer 
(Sigma) with 1% Halt protease inhibitor (Thermo) at a flowrate of 50 μl/min for 2 min, followed 
by a 10 min incubation on ice. This was followed by an injection of 70μL per device at the same 
rate and the effluent was collected. After another 10 min incubation, the remaining effluent in the 
devices was pushed out by pumping air manually. The collected samples were stored at -80 °C 
until used.  
Total protein was measured by standard micro-BCA analysis according to the manufacturer’s 
instructions (Thermo). Lysed protein was mixed with 4x Laemmli buffer with 2-mercaptoethanol 
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at a ratio of 4:1 and heated at 95 C for 7 minutes.  The protein samples were then loaded on a 
10-lane 4-20% SDS gradient gel (BioRad) and run for 47 minutes at 120V in Tris-Glycine-SDS 
buffer (BioRad).  The gel was then transferred to a methanol-activated PVFD membrane at 120V 
for 1hr using BioRad’s Minigel wet transfer system. Following transfer, the membrane was rinsed 
with DI water before drying for 1 hour.  The membrane was then reactivated with methanol, 
rinsed with DI water and submerged in tris-buffered saline with 1% Tween 20 (TBST) before 
blocking in 5% non-fat milk in TBST for 1 hour at room temperature on a rocker.  Primary 
antibodies then incubated overnight in 4 on a rocker at a concentration of 1:1000 for both CD9 
(Cell Signaling) and Beta-Actin (Cell Signaling).  Primary antibodies were rinsed 6 times, 3 quick 
rinses and 3x 5 minutes on a rocker, in TBST before applying anti-rabbit HRP secondary at a 
concentration of 1:1500 (Cell Signaling) for 1.5 hrs on a rocker at room temperature.  Secondary 
antibody was rinsed as previously described and Thermo’s SuperSignal PICO Reagant was 
applied for 5 minutes before imaging using BioRad’s ChemiDoc Imager.   
3.3.7 RNA preparation, RT, and real-time qPCR 
Total RNA from EVs was extracted using Qiazol (QIAGEN). After the EVs were immobilized 
within the device, 120 μl of Qiazol was flowed through the device at 50 μl/min, followed by 10 
min incubation. The device was then processed with another 150 μl at the same flow rate while 
the effluent was collected. After another 10 min incubation, the remaining effluent in the devices 
was pushed out by pumping air manually. The collected samples were stored at -80 °C until used.  
SYBR Green-based real-time qPCR technique was performed for detection of miRNAs, as 
previously described.220 Total RNAs were purified from isolated EVs using a Single Cell RNA 
Extraction Kit (Norgen). Purified RNA amount was measured by NanoDrop Lite 
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Spectrophotometer (Thermo Fisher Scientific). Reverse Transcription Kit (Thermo Fisher 
Scientific) was used to generate single-stranded cDNA from an equal amount of purified RNAs. 
3.3.8 Flow cytometry 
For directly exosome surface staining, EVs were incubated with pre-conjugated FITC mouse anti-
human CD63 (BioLegend) and APC Anti-Human CD81 (BioLegend) for 30 min at room 
temperature. After incubation, the samples were washed with PBS, ultracentrifuged and then 
resuspended in PBS buffer. Stained samples were analyzed using ZE5 (Bio-Rad) flow cytometer 
and FlowJo software (Treestar).  
3.3.9 Uptake of EVs 
Following release from the capture device, EVs were labeled by PKH26 Red Fluorescent Cell 
Linker Kit (Sigma), and Exosome Spin Columns (MW 3000) (Thermo Fisher Scientific) were 
used to remove excess dye as previously described.21 Patu8988t cells were seeded into a 6 well 
plate and allowed to settle and adhere for 48 hours before the dyed EVs were added for a 12 h 
incubation in a 37 cell culture incubator as previously described. Flow cytometry was performed 
to measure mean fluorescence intensity (MFI) of cells.  
3.4 Results and discussion 
3.4.1 Evaluation of EV capture with OncoBean chip  
While previous work assessed the ability of Oncobean to isolate circulating tumor cells from blood 
samples, the present study explored the Oncobean’s capture potential and throughput for isolating 
extracellular vesicles. Figure 3.1 schematically illustrates EVs being captured on the Oncobean’s 
antibody-coated bean-shaped microposts. The increasing cross-sectional area in radial flow design 
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provides a decreasing flow velocity from inlet to outlet, which allows for higher flow rate 
compared to linear flow devices. The high surface area provided by the bean-shaped microposts 
also increases the contact of EVs with capture antibodies, thus enabling high capture at high flow 
rates.  
 
Figure 3.1 Schematic illustration of OncoBean Chip and EV isolation.  
The design of the device can be seen in the previous report. In general, the bean posts are 50 μm 
in width, 118 μm along the longest axis, and 100 μm in height. The posts were placed 25-32 μm 
apart from each other. The device surface functionalized with Neutravidin can be coated with 
desthiobiotin-conjugated antibody that recognize surface markers of EVs. The EVs are captured 
by flowing samples through the chip. Compared to biotin, desthiobiotin has a lower binding 
affinity to avidin, thus facilitating a release mechanism for the EVs. Though the introduction of 
the biotin, the desthiobiotin‐antibody‐EV complex releases from the Neutravidin coated surface, 
allowing for EV collection. 
 
To demonstrate the ability of the OncoBean chip to perform high-throughput isolation of EVs, we 
used the two most common sources of EVs: plasma and cell culture media. First, we used 
biotinylated CD63 and CD9 antibodies as capture antibodies to optimize the flowrate and sample 
volume for EV isolation.   With the goal of minimizing the processing time, we fixed the 
processing time at 1 hour and tested the capture using varying sample volumes to determine the 
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capture capacity of the device. Protein was extracted by flowing RIPA extraction buffer through 
the device post EV capture. We used the protein concentration measured by microBCA kit to 
quantify the EVs captured. As can be seen in Figure 3.2A, when the volume of serum was increased 
to 1200 μl, the protein concentration reached the maximum value and further increasing the serum 
volume did not increase the protein concentration. For cell culture media, the chip was capable of 
processing up to 10 mL of culture media in an hour, demonstrating high throughput EV isolation 
(Figure 3.2B). However, the protein concentration decreased greatly at flow rates higher than 10 
ml/hr. This could be caused by the limited contact time between the EVs and antibodies. Further, 
we performed Western blot analysis on the protein extracted from the chip to verify the EV capture, 
as shown in Figure 3.2C. The presence of CD9, a specific exosome marker, was confirmed in both 
culture media and plasma samples, and β-actin was used as a loading control. Additionally, 
immunofluorescence staining with CD81 and CD9 antibodies further demonstrated the capture of 




Figure 3.2 Characterization of EVs captured using OncoBean chip.  
(A-B) Protein levels in EVs isolated from A) Serum and B) cell culture medium. (C) a 
representative western blot analysis of the proteins from EVs isolated from OncoBean using anti-





Figure 3.3 3D images by confocal scanning microscopy to confirm the capture of EVs with 
Oncobean chip. 
The captured EVs were strained using (A) CD81 and (B) CD9 antibody conjugated with 
fluorescein isothiocyanate.   
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In addition to the protein analysis, we also evaluated our device for its applications in performing 
miRNA analysis of EVs.  A variety of different types of RNA molecules have been identified in 
EVs.   Messenger RNAs (mRNAs), long non-coding RNAs (lncRNAs), ribosomal RNA (rRNA), 
microRNAs (miRNAs) and the fragments of these intact RNA molecules have all been 
identified.221 MiR-21, miR-155 and miR-200 have been shown to be enriched in EVs and their 
expression levels have been correlated with poor prognosis in pancreatic cancer.222 To test the 
capabilities of our device to capture EVs for miRNA analysis, we performed RT-PCR to measure 
the level of miR-21, miR-155 and miR-200 in the EVs. Similar to the previously reported 
pancreatic cancer EVs, we observed enrichment of miR-21, miR-155 and miR-200 in the device 
isolated EVs (Figure 3.4). The characterization of EV protein and miRNA demonstrates the utility 
of the Oncobean Chip for downstream EV analysis after high throughput capture of both low and 
high sample volumes.  
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Figure 3.4 Real-time quantitative PCR analysis on captured EVs. 
(A) miR-21, (B) miR-155, (C) miR-200a, and (D) miR-200b expressions from device isolated EVs. 
The RNA was obtained by lysing the captured EVs in the device and quantified using the real-
time quantitative PCR (RT-qPCR).  Individual miRNA expression levels are shown in bar graphs. 
 
 
3.4.2 Release and harvest EVs from the device 
A critical disadvantage of using biotin-conjugated antibodies for EV capture is the irreversible 
binding between biotin and avidin, hindering the harvest of intact EVs from the device. To 
overcome this challenge, we used desthiobiotin-conjugated anti-CD63 instead of biotinylated anti-
CD63 to capture EVs. Compared to biotin-avidin binding, desthiobiotin-avidin binding can be 
 68
reversed in mild conditions because of the   lower binding affinity between desthiobiotin and avidin. 
When we used desthiobiotin-conjugated antibody instead of biotinylated antibody, immobilized 
EVs within the device were released through exchange reactions as illustrated in Figure 3.1. The 
stronger affinity between the biotin and neutravidin causes the replacement of desthiobiotin with 
biotin, and thus enabling the release of the EVs from the neutravidin-coated surface.  
Optimization studies were conducted in order to determine a reasonable biotin concentration that 
allowed for effective release of EVs from the device. Pre-purified EVs from healthy plasma 
(System Biosciences) were captured using desthiobiotin-conjugated anti-CD63 on the Oncobean 
chip and the released EVs were then quantified with NTA analysis. As shown in Figure 3.5A, the 
concentration of released EVs increased along with increasing concentrations of biotin and reached 
a maximum at a concentration of 0.5 mM. This result led us to use 0.5 mM for all further 
experiments to achieve effective release of EVs.  In addition to the biotin concentration, we also 
evaluated the influence of biotin solution incubation time. However, as illustrated in Figure 3.5B, 
the incubation time was not a significant factor for EV release. Figure 3.5C and 3.5D shows the 
concentration of EVs collected after release from the outlet at different sample volumes using the 
0.5mM biotin solution. These graphs showed that our device can harvest EVs from up to 900 μl 
of serum or 10 ml of cell culture medium. To the best of our knowledge, this is the highest 




Figure 3.5 Characterization of EVs isolated using the OncoBean chip.  
(A-B) NTA analysis of harvested EV with varying (A) biotin concentration and (B) incubation 
time for the release of EV using pre-purified EVs (System Biosciences). (C-D) NTA measurement 
of EVs harvested from (C) plasma and (D) cell culture media. (E-F) Electron microscope images 
showed the presence of EVs immobilizations (E) before and (F) after the biotin introduction (bars 
= 1 m). 
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To confirm the successful release of EVs from the chip, SEM images were taken showing the 
device with and without the injection of biotin, or with and without EV release. The images clearly 
showed that most of the EVs captured on the chip were released after the biotin. (Figure 3.5E-F), 
and thus further validating our ability to capture and release EVs form microfluidic chip. 
3.4.3 Characterization and cell uptake of harvested EVs   
Accumulating evidence has shown that EVs can act as powerful mediators of cell-to-cell 
communication, facilitating various biological events. Importantly, EVs and their cargo have been 
shown to play important roles in disease progression. Therefore, harvesting EVs that are functional 
is important for in-vivo and in-vitro studies. To demonstrate that the captured and released EVs 
are functional and preserve their surface markers, we performed flow cytometry analysis to 
examine EV surface markers and cellular internalization of EVs. 
We used direct flow cytometry to examine two common EV surface markers, CD63 and CD81, 
on EVs isolated using the Oncobean with release and ultracentrifugation.  As shown in Figure 
3.6A, the population of positive EVs from ultracentrifugation is found in the top right 
demonstrating the presence of both CD63 and CD81 on each EV. Similar to the ultracentrifuged 
EVs, device isolated and released EVs have more than 99% CD63 and CD81 positive populations 
(Figure 3.6B). This data not only demonstrated that these vesicles represent EVs but also 
highlighted a sensitive method for surface marker characterization of EVs using flow cytometry. 
Therefore, this approach can be used to differentiate and identify heterogenous populations of EVs, 
thus providing insights into identifying EV surface markers.  
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Figure 3.6 Flowcytometry analysis. 
Flowcytometry analysis of (A) ultracentrifuged and (B) device isolated and released EVs. The 
anti-CD63 antibody conjugated with FITC and anti-CD81 antibody conjugated with APC were 
used to immunolabel the EVs. 
 
The goal of recovering viable EVs from a sample is to study the influence of EVs on the behavior 
of recipient cells after internalization. In order to demonstrate the biological functionality of 
released EVs, we demonstrate that they can be internalized by cancer cells. To do this, we 
compared internalization between EVs isolated from cell culture media using both the Oncobean 
device and ultracentrifugation. To examine whether EVs are taken up by Patu8988t cancer cells, 
we pre-labeled isolated EVs with PKH green dye and incubated them with Patu8988t cells for 12h 
and analyzed their internalization into the cancer cells using flow cytometry. As indicated by the 
higher green peak, the ultracentrifuged sample had similar uptake to the device-released EVs while 
they both had markedly more uptake into cells than the no-EV negative control using only PKH 
dye. This demonstrated that EVs are indeed taken up by Patu8988t cancer cells.  Additionally, we 
found that device isolated EVs were similarly functional compared to the ultracentrifuged ones 
(Figure 3.7A and Figure 3.7B).   
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Figure 3.7 EV uptake by cells. 
(A) Flow cytometry analysis shows uptake of device-derived and ultracentrifuged EVs by 
Patu8988t cells. The EVs were pre-labeled with PKH67 dye before the uptake. Two samples 
without added EVs were used as negative controls: one with PKH dye, one without PKH dye. (B) 
The comparison of mean fluorescence intensity (MFI) of cells treated with EVs to the negative 
control of cells with no EVs. (C) PKH67-labeled EVs (green) were trafficked to lysosomes labeled 
by Lysotracker (red). The traffic of PKH67-labeled EVs through lysosomes was confirmed by the 
colocalization of PKH67 and Lysotracker in Patu8988t cells, as indicated by arrowheads.  The 
yellow regions indicate colocalization of green and red, or EVs and lysosomes. 
 
We also studied the intracellular trafficking of internalized EVs to lysosomes in Patu8988t cells to 
further verify the EV uptake. Lysosomes are membrane-bound organelles found in nearly all 
animal cells. They are spherical vesicles which contain hydrolytic enzymes that can break down 
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many kinds of biomolecules. Simply stated, lysosomes are a type of vesicles with a specific 
composition of both its membrane proteins and proteins in its lumen. The lumen's pH (4.5–5.0) is 
optimal for the enzymes involved in hydrolysis.223  Lysosomes are an essential part of the vesicular 
compartment and connect the outside medium with many classes of cellular targets in the cytosol, 
nucleus, mitochondria, endoplasmic reticulum, and Golgi.224 EVs can reach the lysosome through 
endocytosis. The capture of EVs occurs through specific endocytic mechanisms according to the 
nature of the cargo. After uptake, the EVs are routed to early endosomes. From the endosomes, 
the EVs can either be recycled back to the plasma membrane or sorted and targeted for lysosomal 
degradation.  
To verify the migration of EVs into lysosomes, cells were incubated with Lysotracker (red; to label 
lysosomes) and cocultured with PKH67-labeled (green) EVs from human serum and analyzed by 
confocal microscopy. PKH67 detected in lysosomes demonstrated the colocalization of EV and 
lysosomes (Figure 3.7C), demonstrating that the EVs from device are biologically active. 
Using flowcytometry and fluorescent microscopy, we have shown the feasibility of using the 
immunoaffinity based Oncobean device for EV capture and release. We were then able to show 
the uptake of isolated and enriched EVs by cells and confirmed their surface markers using flow 
cytometry. We strongly believe this technology will facilitate studies into the role of EVs as cell-
to-cell communicators.  
3.5 Conclusion 
In this study, we have successfully demonstrated the utility of the high-throughput Oncobean for 
EV isolation from cell culture supernatant and human plasma. The high surface area and radial 
flow design provided by the bean-shaped microposts facilitate capture of EVs not only at high 
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flow rate, but also from larger volumes of media form cell culture supernatant. Furthermore, our 
results indicate that the Oncobean chip facilitates the analysis of EV proteins and RNAs using 
western blot and qPCR. Most excitingly, through desthiobiotin antibody capture and biotin elution, 
we were able to release functional EVs from the device for cell uptake and identification of surface 
markers, which were verified using flow cytometry. We believe our microfluidic device can 











Simultaneous Single Cell Gene Expression and Mutation Profiling 
of Circulating Tumor Cells 
 
4.1 Abstract 
Tumor cell populations are known to be highly heterogeneous. An invasive tumor biopsy has the 
potential to miss these clones due to spatial heterogeneity, while bulk analysis can miss 
information from rare subpopulations. To investigate tumor cell heterogeneity, we developed a 
streamlined workflow to scrutinize rare cells, such as circulating tumor cells (CTCs), for 
simultaneous single cell mutation and gene expression profiles. This powerful workflow 
overcomes low-input limitations of single cell analysis techniques. Here we highlight the utility of 
this multiplexed workflow to unravel inter- and intra-patient heterogeneity in lung CTCs from six 
epidermal growth factor receptor (EGFR) mutant positive non-small-cell lung cancer (NSCLC) 
patients isolated using the high-throughput microfluidic technology, the Labyrinth.  
4.2 Introduction 
The power of targeted therapies, designed to target specific molecular vulnerabilities, was shown 
in non-small-cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth 
factor receptor (EGFR) gene who responded favorably to tyrosine kinase inhibitors (TKIs) 
compared to patients with wildtype EGFR.225 A patient’s eligibility to receive targeted therapy is 
determined by molecular information obtained from tumor biopsies. However, false-negatives 
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resulting from spatial tumor heterogeneity and the risk of missing mutant tumor clones from 
regional tissue biopsies can occur. Alternatively, circulating tumor cells (CTCs) and circulating 
tumor DNA (ctDNA) present in the blood can be accessed through a routine blood draw, termed a 
“liquid biopsy”, which may better capture tumor heterogeneity.226 Both ctDNA and CTCs have 
been used to monitor disease progression and have shown clinical significance across many cancer 
types.227-231 ctDNA, present in low levels in the blood, typically ranging from <0.1% to >10% of 
total cell-free DNA content232, is frequently below the detection limit of technologies such as 
Sanger sequencing and quantitative PCR (qPCR), therefore many groups have focused on next-
generation sequencing and more recently digital PCR (dPCR) to detect tumor-specific 
mutations.232,233  
Currently, the Roche Cobas EGFR mutation test v2 is the only FDA-approved liquid biopsy test, 
used for screening EGFR mutations from ctDNA as a companion diagnostic. However, the 
sensitivity and specificity of the system is only 58.4% and 80.4% respectively for the T790M 
mutation.234  Due to the relatively low efficiency of this test, it is used as a “rule-in” test, meaning 
if the mutation is not detected, it isn’t considered absent, and rather a clinician may consider 
recommending a repeat tumor biopsy before modifying treatment.234,235  
While ctDNA has shown promise, there is still debate about using ctDNA for tumor monitoring. 
ctDNA arises from lysed cells, and therefore represents a bulk snapshot of the tumor. Alternatively, 
CTCs may provide a real-time view of active disease status, and will likely be enriched for highly 
aggressive, treatment-resistant live cells. While CTCs are rare in the blood, typically on the order 
of tens of CTCs per milliliter of blood, many isolation techniques have been developed, most 
commonly using microfluidic technologies.236-238 This enables whole cell analysis, which can 
include genomic, transcriptomic, or proteomic analysis. 
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Initial work in CTCs focused on enumeration and bulk analysis for gene expression using 
techniques such as qPCR or RNA sequencing (RNA-seq). This approach is limited to 
characterizing the sample as an aggregate of the bulk population, therefore missing rare 
phenotypes and may be biased by sample purity from leukocytes remaining in the sample.236,239  
As a result, several groups have developed workflows for single cell analysis to study tumor cell 
heterogeneity, commonly through gene expression or genetic profiling. These analysis techniques 
tend to be labor intensive, time consuming, and expensive.  Due to the low starting material many 
single cell analysis platforms require pre-amplification steps such as whole genome amplification 
(WGA) for genomic aberrations and whole transcriptome amplification (WTA). An inherent 
limitation of pre-amplification is the predisposition for PCR bias and gene dropout.240 Nonetheless, 
single cell RNA-seq (scRNA-seq) has emerged as a common method for transcriptomic analysis, 
important in exploratory studies for prognostic markers. scRNA-seq has revealed intra-patient 
CTC heterogeneity and signatures of highly metastatic cells. Despite its promises, groups have 
reported many inefficiencies and technical limitations, leading to few recovered CTCs proceeding 
through the entirety of the workflow from recovery, library preparation, and sequencing.240 It 
reported that after all these limitations, sequencing only achieves coverage of 15-50% of total 
transcripts.240 
Alternatively, dPCR is a highly sensitive approach facilitating precise and accurate detection and 
quantification of specific nucleic acid target sequences without the requirement of pre-
amplification. In dPCR, individual DNA segments are partitioned into discrete reaction droplets 
through a water-in-oil emulsion following the Poisson distribution. Each droplet acts as an 
individual reaction for PCR amplification. The fluorescent intensity of each droplet is then 
measured in parallel with end-point PCR analysis. This converts data analysis into a binary 
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positive/negative result based on fluorescent intensity, leading to easy data analysis without the 
need for standard curves for quantification, which could be quickly reported back to a treating 
physician.241,242  
Here, we have established a workflow for rapid single cell profiling of CTCs for simultaneous 
gene expression and mutation detection to evaluate how tumor subpopulations evolve over time. 
We screened 58 CTCs from six NSCLC patients with known EGFR mutations and identified intra-
patient heterogeneous mutation profiles in these CTCs.  
4.3 Methods 
4.3.1 Cell culture 
Cells were maintained at 37 °C under normoxic conditions. Cells were grown to 70-80% 
confluence before subculturing using 0.05% Trypsin-EDTA (Gibco). H1975 (EGFR 
L858R/T790M mutant), H1650 (exon 19 deletion) and T47D (EGFR wildtype) cells were grown 
in RPMI-1640 (Gibco), and A549 (EGFR wildtype) were grown in F-12 (Gibco), each 
supplemented with 10% FBS (Sigma) and 1% Antibiotic-antimycotic (Gibco). Media was 
exchanged every 48-72 hours between subculturing. Cell lines were routinely tested and reported 
negative for mycoplasma contamination (Lonza).  
4.3.2 RNA extraction & cDNA synthesis 
For cell line experiments, total RNA was purified using miRNeasy mini kit (Qiagen) following 
the manufacturer’s protocol. RNA concentration and purity were evaluated using a NanoDrop ND-
1000 spectrophotometer. For each sample, 2000 ng of total RNA was loaded into each reverse 
transcription reaction. cDNA was synthesized using SuperScript IV VILO Master Mix with 
ezDNase Enzyme (Invitrogen) following the manufacturer’s protocol. All purified RNA and 
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cDNA products were handled in a PCR workstation (AirClean Systems) to prevent nuclease 
contamination.  
4.3.3 Experimental protocol for labyrinth (patient sample processing) 
The experimental protocol was approved by the Ethics (Institutional Review Board) and Scientific 
Review Committees of the University of Michigan and all patients gave their informed consent to 
participate in the study. All patients had a diagnosis of EGFR mutant lung adenocarcinoma. 
Briefly, blood samples were collected in EDTA tubes and processed through the Labyrinth within 
2 hours of collection. RBCs in the blood samples were removed using density separation with 
Ficoll-Paque™ PLUS Media (GE Healthcare) following the manufacturer's protocol prior to 
processing in the Labyrinth. 
The plasma and blood mononuclear cells (PBMCs) layers were collected and diluted with PBS 
(1:5). The diluted sample was then processed through the Labyrinth at 2500 L/min, and the 
product from outlet 2 was collected. To achieve a higher purity, the second outlet’s products of the 
Labyrinth (single) were processing through another Labyrinth (double).   
4.3.4 Immunofluorescent staining and CTC enumeration 
The product of single Labyrinth from outlet 2 was processed using a Thermo ScientificTM 
Cytospin Cytocentrifuge. A poly-lysine coated slide was placed into the cytospin funnel and 250 
μL of sample was added to each cytospin funnel and cytocentrifuged at a speed of 800 rpm for 10 
min. Samples were fixed on the cytoslides using 4% paraformaldehyde (PFA) and cytocentrifuged 
at the same conditions as described above. Slide samples were permeabilized by applying 0.2% 
Triton X-100 solution for 3 min. Slides were then washed with PBS (X 3) for 5 min and blocked 
using 10% donkey serum for 30 min at room temperature.  
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The panel of antibodies (anti-human CD45 (mouse IgG2a) (Bio-Rad), anti-human Pan-cytokeratin 
(CK) (mouse IgG1) (Bio-Rad), anti-human EpCAM, biotinylated (goat IgG) (R&D Systems), and 
anti-human vimentin (rabbit IgG) (Abcam) were used. The slides were then incubated with a 
cocktail of primary antibodies (anti-CD45, anti-PanCK, anti-EpCAM, and anti-Vimentin) 
overnight at 4˚C, followed by PBS wash (X 3) for 5 min the following day. Slides were incubated 
in the dark with secondary antibodies secondary antibodies goat anti-mouse IgG2a Alexa Fluor 
488 (AF 488) (Invitrogen), goat anti-mouse IgG1 Alexa Fluor 546 (AF 546) (Invitrogen), goat 
anti-rabbit Alexa Fluor 647 (AF 647) (Invitrogen), and Stepavadin, Alexa Fluor 750 conjugate 
(Invitrogen) for 1.5 hour at room temperature. Finally, slides were washed with PBS (X 3) for 5 
min and mounted using Prolong Gold Antifade Mountant with DAPI (Invitrogen). The stained 
slides were imaged using a Nikon TI inverted fluorescent microscope at 20X magnification for 
enumeration. 
The tiled images generated from the scans were manually viewed and CTCs were determined 
based on their fluorescent signals in each channel. A CTC was counted as DAPI+/CK+ (AF 
546)/CD45- (AF 488). The CTC phenotype was determined based on the presence/absence of 
phenotype markers. EpCAM was used an epithelial marker, and vimentin was used as a 
mesenchymal marker. CTCs (DAPI+/CK+/CD45-) were considered epithelial if 
EpCAM+/vimentin-, mesenchymal if EpCAM-/vimentin+, and EMT (epithelial to mesenchymal 
transition) if EpCAM+/vimentin+.  
4.3.5 Fluidigm C1 & Biomark HD 
Cell suspensions were loaded onto the C1 Single-Cell Auto Prep IFC for Preamp (10-17µm) 
(Fluidigm) following the company’s protocol with on-chip cell staining. The cells were stained 
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with FITC pre-conjugated anti-human CD45 (Biolegend), as a negative marker. After loading, 
each cell capture site was manually imaged.  
For targeted pre-amplification, a pre-designed panel of 96 genes implicated in cancer progression, 
phenotype, and aggressiveness was used to characterize the cells. After the C1 run was complete, 
the sample was diluted using C1 DNA dilution reagent. For the dPCR data generated using lung 
cancer cell lines, the C1 product was diluted to 28 L, based on the manufacturer’s protocol. For 
the lung CTC samples, the C1 product was diluted to only 12-15 L to keep the sample more 
concentrated for dPCR testing. 2 L of this sample was further diluted to 4 L using the C1 DNA 
dilution reagent and was used for gene expression analysis on the Biomark HD system (Fluidigm) 
following the manufacturer’s protocol, while the remainder was used for mutation detection.  
4.3.6 Mutation detection using dPCR 
The RainDrop system (RainDance Technologies) was used for dPCR mutation detection. In brief, 
the PCR mix was prepared using TaqMan SNP Assay (Life Technologies), TaqMan Genotyping 
Master Mix (Applied Biosystems), and droplet stabilizer (RainDance Technologies). cDNA was 
mixed with the PCR mix in PCR tubes to generate 25 L reactions and loaded onto the Source 
Chip (RainDance Technologies). The PCR reaction is emulsified with Carrier Oil (RainDance 
Technologies) into approximately 4 million, 5 pL sized droplets with single molecule loading, and 
collected into an 8-tube PCR strip (Axygen). After droplet generation, the PCR tubes were 
transferred to the thermocycler for 45 rounds of PCR amplification. The TaqMan SNP assays 
contain two probes, one for wildtype EGFR sequence the other for the mutant EGFR sequence, 
with VIC and FAM probes, respectively. The TaqMan exon 19 deletion assay contains probes for 
19 common exon 19 deletion variants, all with a FAM probes. The PCR tubes containing the 
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amplified samples were then transferred onto the Sense Machine (RainDance Technologies) where 
the endpoint fluorescence intensity of each droplet is measured. Gating templates were generated 
using positive and negative cell line controls.  
4.4 Results and discussion 
4.4.1 Single cell co-analysis workflow 
The development of a highly sensitive approach could overcome the limitations of liquid biopsies, 
such as rarity of the targets and low volume constraints, facilitating early detection of resistance 
mutations. Here, our workflow is optimized for ultra-low input and can consistently detect the 
presence of these EGFR mutations at the single cell level (Figure 4.1). To interrogate CTCs with 
single-cell resolution, we integrated our previously developed inertial microfluidic isolation 
technology, the Labyrinth and the commercial Fluidigm integrated fluidic chip (IFC).243 First, 
CTCs are enriched from peripheral blood using the Labyrinth, a high-throughput, label-free 
technology, that isolates CTCs from blood cells based on cell size. The microfluidic device 
incorporates curved channels and sharp corners to efficiently focus both CTCs and white blood 
cells (WBCs) into separate streamlines, and has been previously shown to yield >90% recovery of 
CTCs  and >90% WBC removal.243 To improve CTC purity and facilitate better compatibility with 
current single cell isolation technologies, the remaining WBCs are depleted using an 
immunoaffinity capture microfluidic device functionalized with a cocktail of antibodies against 
common WBC targets including CD45, CD15, and CD11b. Finally, the ultra-pure CTC suspension 
is loaded onto the Fluidigm IFC, which streamlines on-chip single-cell capture, lysis, reverse 
transcription (RT), and targeted PCR pre-amplification of up to 96 single cells. For pre-
amplification and gene expression, we chose a targeted analysis because it has been previously 
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reported single cell PCR offers all the benefits of bulk qPCR analysis including high sensitivity, 
specificity, and reproducibility.  
 
Figure 4.1 Circulating tumor cell sample processing schematic overview for single cell 
analysis.  
Blood is collected from EGFR mutant NSCLC patients and. The blood sample is process through 
the Labyrinth, a size-based sorting microfluidic technology to isolate CTCs (~15-20μm) from 
WBCs (~10-12μm). The CTC sample is loaded onto the Fluidigm C1 for single cell capture and 
processing. The resultant single cell sample is then used for gene expression and EGFR mutational 
profile co-analysis. 
 
Due to the C1 processing protocol, the generated complementary DNA (cDNA) is fragmented due 
to RT with random primers. This is optimal for the gene expression and EGFR mutation co-
analysis because it allows for better coverage of the entire transcript. The pre-amplification on the 
C1 IFC is a targeted gene panels and occurs only within the region of interest for gene expression 
(Table 4.1), while the regions of the EGFR mutations (exons 19-21) remain un-amplified. This 
leaves an untampered view of not only the EGFR mutational burden but the relative transcription 
of wildtype and mutant alleles. 
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Table 4.1: Lung cancer 96 gene panel used for Biomark HD qPCR 
 
To achieve the simultaneous gene expression and mutation detection from a single cell, a small 
portion of the pre-amplified cDNA was used for gene expression profiling of the pre-designed, 
targeted 96 gene panel with highly multiplexed qPCR via the Biomark HD Dynamic Array 
(Fluidigm, USA).243 The remaining single cell sample is analyzed for mutations using a duplex 
assay for the wildtype and mutant-specific sequences on the RainDrop dPCR system (RainDance 
Technologies, USA).  
4.4.2 Validation of EGFR mutation detection using digital PCR (dPCR) 
Three major EGFR driver mutations, L858R, T790M and exon 19 deletions, were chosen for this 
study because of their implications on patient sensitivity to TKI therapy. NSCLC patients 
harboring activating mutations, L858R or exon 19 deletions, in EGFR have a dramatic response 
to TKI therapy, but develop resistance after about 10 months through a secondary mutation, most 
commonly T790M.233,244,245 To validate the performance of the dPCR platform, we detected and 
quantified the mutant transcripts of bulk cDNA derived from H1975 (L858R and T790M) and 
H1650 (exon 19 deletion) cell lines. The cDNA was analyzed for the presence of EGFR L858R, 
T790M and exon 19 deletions at loadings ranging from 0.05ng-50ng (Figure 4.2). For the point 
mutations, L858R and T790M, discrete mutant and wildtype gates were generated based on the 
positive controls. For the exon 19 deletion, the TaqMan assay contains a pool of 19 common exon 
19 deletion variants, which caused a larger population spread, even in control cell lines, and 
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required a quadrant-based gating, as shown in Figure 4.2A.  Linear regression analysis of the 
fraction of positive droplets versus cDNA loading exhibited a linear relationship (R2=0.99), 




Figure 4.2 Validation of EGFR mutation detection using RainDance dPCR system.  
(A) Representative dPCR plots of lung cancer cell line controls, H1975 (L858R/T790M), H1650 
(exon19 deletion) and A549 (wildtype), for the three tested EGFR mutations, L858R (left), T790M 
(middle), and exon 19 deletion (right). For the point mutations (L858R and T790M, Taqman assays 
detect the wildtype (VIC channel) and mutant (FAM channel) variants. For exon 19 deletion, the 
assay screens for 19 common deletions (FAM channel). (B) Dynamic linear range of positive 
droplet counts using serial dilutions of cDNA for L858R (left), T790M (middle) and Exon 19 
deletion (right) (Range = 0.05ng-50ng). Droplets counts for L858R and T790M results used cDNA 
generated from H1975 cells and exon 19 deletion results used H1650 cells.  
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4.4.3 Establishing robust single cell gene expression and EGFR mutation co-
analysis 
To establish the single cell co-analysis workflow, H1975 and H1650 cells were processed on the 
aforementioned C1 IFC chip followed by multiplexed qPCR and dPCR analysis (Figure 4.3A). 
Figure 4.3B shows consistent detection of EGFR wildtype and mutant transcripts at the single cell 
level in H1975 cells. A heterogeneous expression of total EGFR was observed in H1975 cells with 
an average of 57 EGFR droplets per cell (range 17-88) for the L858R mutant duplex assay and 41 
positive EGFR droplets per cell (range 13-72) for the T790M mutant duplex assay. The H1650 
cells tested with the exon 19 deletion assay showed an average of 11 positive droplets per cells 
(range 3-14).  Figure 4.3C shows that the mutant population contained approximately 5 times 
higher droplet counts than the wildtype population (ratio range 2.5-9.3) in both the L858R and 
T790M duplex assays. The variations in the mutation-wildtype ratio demonstrate cell-to-cell 
heterogeneity, highlighting the utility of single cell analysis. The average of the H1975 single cells 
matched the bulk population for both mutation assays (Figure 4.3C). This higher expression of the 
mutant transcript is consistent with an increased EGFR mutant copy number in H1975 cells.246  
Even within a cell line, heterogeneous gene expression profiles (Figure 4.3E) and EGFR transcript 
counts based on dPCR were observed (Figure 4.3B), highlighting the need to dissect heterogeneity 
of tumor cells at a single-cell resolution. As can be seen, the expression of common NSCLC 
phenotype markers, such as EGFR, CD44, and EPCAM, showed cell to cell variability in each 
H1975 and H1650 single cells and could be used to characterize phenotypic subpopulations. 
Moreover, there was a strong concordance between EGFR gene expression measured by qPCR 
and absolute EGFR droplet count in H1975 single cells (Figure 4.3F), further confirming the 




Figure 4.3 Validation of single cell workflow for gene expression and EGFR mutation 
analysis using lung cancer cell lines.  
(A) Representative dPCR plots of H1975 and H1650 single cells for EGFR L858R and T790M 
point mutations and exon 19 deletion, respectively. (B) Single cells express heterogeneous total 
EGFR levels based on the combined mutant and wildtype droplet counts. Positive droplet counts 
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for each cell are shown. L858R: n= 13 H1975 cells. T790M: n= 14 H1975 cells. Exon 19 deletion: 
n= 5 H1650 single cells. Due to the noise of the exon 19 deletion assay, a threshold for positive 
detection is shown. (C) Comparison of relative mutant and wildtype EGFR expression in single 
droplet counts in H1975 single cells. Ratio of mutant:wildtype droplet counts shown above each 
cell. L858R: n=13 H1975 cells. T790M: n=14 H1975 cells. (D) The average ratio of 
mutant:wildtype droplet counts in H1975 single cells was compared to bulk cells in the L858R and 
T790M assays. L858R - bulk: n=12, single cells: n= 13. T790M - bulk: n=9.  single cells: n= 14. 
(E) Heatmap of H1975 and H1650 single cells of 28 genes shows heterogeneous gene expression 
within each cell line. (F) The correlation between gene expression and total droplet counts of 
mutation and wildtype in the same single cells. Each data point denotes a single cell.  The gene 
expression and mutation droplet count data of each single cell are normalized to a cell that has the 
highest gene expression and mutation droplet counts. 
4.4.4 Single cell characterization of NSCLC CTCs 
After establishing this single cell workflow, CTCs isolated from NSCLC patients were evaluated. 
NSCLC patients were enrolled at the University of Michigan Rogel Cancer Center, under an IRB 
approved protocol and contained known EGFR mutations based on primary tumor characterization.   
CTCs were isolated from six metastatic NSCLC patients positive with known EGFR mutations 
(Figure 4.4B). CTCs were isolated using the previously described Labyrinth microfluidic 
technology.243 A small portion of the CTC sample was used for enumeration with 
immunocytochemistry (ICC) (Figure 4.4A). CTCs were identified as being cytokeratin (CK) 
positive and CD45 negative (Figure 4.4A) and had highly heterogeneous expression of EMT 
markers. Some CTCs showed the expression of epithelial marker, EpCAM, while others showed 
expression of mesenchymal marker, vimentin (vim). A subset of CTCs showed dual expression of 
EpCAM and vim, suggesting an intermediate state within EMT (Figure 4.4A). We observed a wide 
range of CTC numbers across the patients (range 38.5-201.4 CTCs/mL blood), and it was noted 
that the patients who were progressing at the time of blood draw tended to have higher CTC 
numbers than those who have stable disease (Figure 4.4B,C).  
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From these six patients, the remainder of the CTC sample was used for single cell analysis via the 
C1 platform. The sample was stained on the IFC for CD45, and only CD45 negative cells were 
processed for mutation screening. Individual CTCs were tested for the presence of tumor tissue-
matched EGFR mutations (Figure 4.4B, 4.5A). In 5/6 patients, we were able to identify the 
presence of these EGFR mutations (Figure 4.5A, C-E) in at least one CTC. In patients 1 and 3-6, 
the CTCs contained patient-matched EGFR mutations, whereas for patient 2, dPCR signal was 
within the level of uncertainty to confidently classify the CTCs as containing exon 19 deletion. 
We did not observe any correlation between the CTC number and the percent of CTCs that tested 
positive for EGFR mutations. Nor was it observed that the percent of EGFR mutation positive 




Figure 4.4 Patient characteristics and CTC analysis.  
(A) Representative images of heterogeneous CTCs and different EMT phenotypes based on 
EpCAM (epithelial) and vimentin (mesenchymal) ICC. (B) Patient mutation based on tumor 
profiling and treatment regimen. (C) CTC enumeration across the 6 patients based on 
immunofluorescent staining. (Range = 38.5-201.4 numbers/ml). 
For the subset of patients with the point mutations, L858R and T790M, in all CTCs we exclusively 
observed a heterozygous EGFR mutation expression, with variable mutation to wildtype 
expression ratios. For all tested cells, there was a higher abundance of wildtype expression 
compared to the mutant allele. This could be caused by the altered copy number variation profiles 
within the CTCs or differential gene expression regulation. Our data demonstrated the significance 
of single cell analysis to identify homozygous and heterozygous mutations, which would be lost 
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in bulk analysis. Further, with single cell analysis we could also evaluate the relative expression 
of each allele. 
The remaining portion of the single cell sample was used for gene expression of the pre-designed 
96-gene panel. dPCR was able to detect the presence of EGFR transcripts that was below the limit 
of detection on the multiplexed qPCR system (Figure 4.5B). Interestingly, the genes most 
commonly expressed in the CTCs were regulators of cell proliferation, such as estrogen receptor 
1 (ESR1) and anti-apoptosis, such as BCL2, or differentiation, such as TGFβ1. It has been shown 
that ESR1 expression and EGFR mutations tends to occur more frequently together in 
NSCLC.247,248 ESR1 expression in lung cancer has been associated with poor patient prognosis, 
while ESR2 correlation with patient prognosis appears to be dependent on cellular localization. 
Estrogen, through estrogen receptor signaling, can activate the signaling pathway downstream of 
EGFR, PI3K/AKT. This can lead to EMT and promote cancer metastasis.248 Additionally, there 
have been clinical trials evaluating the efficacy of EGFR TKI therapy in combination with estrogen 
receptor antagonists and in a pilot study treatment was well tolerated and showed efficacy.248  
TGFβ1, known to be involved in EMT, expression showed a positive correlation with the 
expression of ER in the CTCs. Interestingly, the CTCs with the highest ER and TGFβ1 also had 
has BCL2 expression, an inhibitor of apoptosis.249  
EGFR expression was below the limit of detection on the qPCR analysis but was detected using 
the dPCR (Figure 4.5). Notably, for patient P06, a subset of the CTCs demonstrated a high level 
of exon 19 deletion EGFR expression, and also exhibited a gene expression profiles consistent 





Figure 4.5 Patient tumor-matched mutations detected in CTCs.  
(A) Summary of mutant single CTCs identified in each of the 6 patients (n=58). (B) Heatmap 
showing heterogeneous gene expression of single CTCs from two NSCLC patients (n=9). (C-E) 
Primary tumor matched mutations detected in patients’ single CTCs for (C) L858R (n=3), (D) 





In conclusion, we described a multiplexed, single-cell analysis method targeting gene expression 
and mutation detection from single circulating tumor cells. Compared to current clinical testing, 
this multiplexed method enables rapid turnaround from sample collection to result. By integrating 
ultra-sensitive technologies, a single cell can be profiled for multiple characteristics. We 
demonstrated the feasibility of our method to simultaneously quantify mutant transcripts and 
profile the gene expression of a single cell. To the best of our knowledge, this is the first use of 
dPCR for single cell analysis in CTCs, and we have highlighted the clinical relevance of this work. 
Due to the genetic instability and dynamic changes a tumor undergoes throughout treatment, real-
time CTC monitoring of tumor evolution could help continually optimize a patient’s treatment 
plan, improving patient outcome. The single-cell resolution enables the early detection of 
emerging rare clones that could lead to therapeutic resistance from a routine blood draw, allowing 
for more predictive analysis of targeted therapy response. In the case of NSCLC, co-analysis could 
reveal if specific clones harboring EGFR mutations are primarily utilizing EGFR-related pathways, 
or if another driver mechanism may be being utilized. The coupled gene expression and mutation 
profiling using a simple workflow that doesn’t require complex computational analysis could be 
easily integrated into a clinical setting, enabling real-time monitoring and could ultimately 











Conclusions and Future Directions 
 
5.1    Summary of research 
5.1.1 Microfluidic technologies for the isolation and characterization of 
circulating extracellular vesicles and evaluation of their functional role in 
amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative without an adequate 
biomarker to detect the disease. The study of EVs have offered valuable information to find new 
diagnostic and prognostic biomarkers for neuron degenerative diseases. In this study, we explored 
the potential of EV miRNAs as biomarkers of ALS. We used an immuno-affinity-based 
microfluidic device, the Exochip, for isolation and quantification of EVs from blood and tissues, 
including spinal cord and frontal cortex of ALS patients and healthy controls. The western blot 
and electron microscopy validated the vesicle isolation, and NanoString profiling was used to 
evaluate EVs miRNA signatures. Although there were no significant differences in EV 
concentrations between the ALS and control subjects, a total of 60 EV miRNAs were observed to 
be significantly dysregulated. The pathway analysis of predicted miRNA target genes also 
suggested the involvements of these miRNAs in ALS and neuron degeneration. This study showed 
the potential of EV miRNAs as novel biomarkers for ALS. Further studies on these miRNAs with 
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larger cohorts of patients may contribute to an understanding of the pathological mechanisms 
underlying ALS progression.  
5.1.2 Microfluidic device for high-throughput affinity-based isolation of 
extracellular vesicles  
Immuno-affinity approaches for EV isolation utilize the antibodies targeting the surface markers 
of EVs, providing higher specificity and purity over the existing physical approaches. However, 
the immuno-affinity methods suffer from certain limitations including low-throughput and the 
inability to release the EVs from the capture substrate. To overcome these limitations, we 
reprogramed the Oncobean chip, a immuno-affinity based microfluidic device that was developed 
to capture circulating tumor cells. The radial flow design and bean-shaped microposts 
functionalized with CD9, CD63, and CD81 antibodies allow for high-throughput isolation of EVs 
from plasma and culture media. Furthermore, by using the desthiobiotin antibody, the captured 
EVs can be released from the device with biotin elution. The cell uptake and intercellular migration 
of EVs verified by flow cytometry and confocal microscopy demonstrated that the released EVs 
are functional. We believe the proposed technology can facilitate the studies on the role of EVs as 
cell-to-cell communicators and identification of EV markers. 
5.1.3 Simultaneous single cell gene expression and mutation profiling of 
Circulating Tumor Cells (CTCs) 
Dissecting tumor cell heterogeneity is critical for understanding the tumor progression and 
resistance to therapies. However, the cellular heterogeneity and diversity are usually overlooked 
in bulk cell analysis, and thus missing important information from rare subpopulations. Here, we 
developed a workflow for rapid single cell profiling of CTCs for simultaneous gene expression 
and mutation detection. We demonstrated the feasibility of our method to simultaneously quantify 
mutant transcripts and profile the gene expression of a single cell with lung cancer cell lines. Our 
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data showed that there is cell-to-cell variation in gene expression and mutation transcript counts 
even in the homogenous cell population. Moreover, we demonstrated the utility of the workflow 
to study intra-patient heterogeneity by analyzing 58 CTCs from six NSCLC patients with known 
EGFR mutations.  
5.2    Future directions and limitations  
5.2.1  EV in ALS 
In this thesis work, miRNA signature in EVs derived from tissues were profiled using NanoString 
technology. By comparing the miRNA profiles of ALS patients and healthy control, a total of 60 
dysregulated EV miRNAs were identified, suggesting the potential of EV miRNAs as biomarkers 
for ALS. However, there were some limitations in this study.  
One of the major limitations is the reliance on CD63 for EV capture.  Using our technology, we 
were able to isolate only CD63 positive EVs. However, studies have demonstrated the presence of 
CD63 negative EVs. Isolation solely based on CD63 may exclude important populations of EV. 
Method to address such concerns is using a cocktail of antibodies that are also common markers 
for EVs, such as CD9 and CD81. Furthermore, antibodies that targets specific EV populations can 
also be incorporated. For instance, L1 cell adhesion molecule antibody could be used to target EVs 
of neuronal origin. 
Another limitation is the relatively small size of patient cohort (<15 for each tissue). Due to the 
limited availability of brain and spinal cord tissues, cohorts selected in this study were mainly 
based on availabilities, and all patients are sporadic ALS. To generate data that can have significant 
conclusions on implications of EV miRNA in ALS, the data should be verified in larger cohorts. 
Additionally, the uncertainty in the sample collections is also a limitation. The plasma samples 
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were collected from the patients at various stages of ALS while the spinal cord and frontal cortex 
tissues were collected postmortemly, which only reflects the terminal stage of ALS. To address 
such limitations, the dysregulated miRNAs identified in postmortem tissues can be validated with 
samples from central nervous system of patients at different ALS stages, such as CSF.  
Finally, although the pathway analysis in the current study suggested the potential involvement of 
EV miRNAs for neuron degeneration, the influence of EV miRNAs on ALS pathology was not 
experimentally verified. It is important to examine the correlation of transfer of miRNAs via EVs 
with ALS pathology. The future investigation should focus on how the miRNAs regulate the 
cellular functions in CNS through EVs and verify their involvements in ALS pathogenesis. 
Furthermore, to evaluate the utility of EV miRNAs as diagnostic biomarkers, the correlation of 
ALS progression and status with the changes in EV miRNA will also be investigated in the future.   
5.2.2  High throughput capture and release of EVs using OncoBean chip 
In the past two decades, the advancements in microfluidic technologies for EV isolation has 
profoundly improved the understanding of mechanisms involved cancer and neurodegeneration 
diseases. The microfluidic EV isolation can be classified into immuno-affinity approach and 
physical approach. The immune-affinity approach coupled with microfluidic technologies have 
shown higher purity and specificity enrichment of EV. The microfluidic device introduced in this 
report (Chapter 3) made further advancements by incorporating the radial flow microfluidic chip 
with desthiobiotin-biotin release strategy to increase the throughput and harvest the intact EVs. To 
more broadly apply such technology, some potential future steps are worth to be mentioned. 
Although we have demonstrated the ability of the device to capture and release EV from culture 
media and healthy plasma at high throughputs, the Oncobean device should be tested with clinical 
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samples to further validate its application. Optimization will require continued testing on the 
device with other types of samples such as CSF, tissue homogenates, and urine. Body fluids have 
different physical properties and non-vesicular components that requires different operation 
conditions for the device to maintain the yields with reliable quality. The performance of the chip 
with different body fluids should be evaluated by analyzing the quantity, size, and purity of 
released EV. Moreover, further work should involve examining the feasibility of performing other 
downstream analysis on genomic and proteomic contents of these EVs, such as NGS, ELISA, and 
dPCR.  
More importantly, the major reason for releasing EVs is to facilitate the study on how the EVs 
change the genotype and phenotype of the cells after their internalization. Therefore, to apply the 
device for such studies, the device should be tested and optimized with other desthiobiotin-
conjugated antibodies that target EVs with different cell origin. More studies also need to be done 
to further evaluate the influences of uptake of released EVs by analyzing the genomic and 
proteomic alterations in the recipient cells. Characterizing the uptake and the intracellular tracking 
of these EVs in different cells can provide valuable information in EV biogenesis. We believed 
further development of this chip and its application will hold promise to enable the study of EVs 
on their composition, properties, and functions in various cell types.  
5.2.3  Single cell analysis 
In chapter 4, we presented a workflow integrated different microfluidic technologies to achieve 
the CTC isolation and characterization at the single cell level. Although the described workflow 
demonstrated the ability to assess the heterogeneity among CTCs with high sensitivity, the 
workflow is not yet perfect. Some limitations of the proposed workflow need to be addressed. 
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Another major limitation that needs to be improved is the challenge of the contaminating 
leukocytes. The proposed workflow utilizes a previously developed microfluidic device, the 
Labyrinth, to concentrate the CTCs from patient blood. After 88% WBCs are sorted out from the 
sample by the Labyrinth, we used a microfluidic device with cocktail of antibodies, including 
CD45, CD11b, and CD15, to further remove the WBCs. However, the remaining WBCs in the 
suspension still cause the low recovery of single CTCs in C1 chip. In the future, other technologies 
should be incorporated to further enhance the WBC deletion. 
The other potential area of improvement will be the workflow is multiplex dPCR. Although the 
dPCR mutation analysis workflow provide precise and sensitive quantification of mutation 
transcripts, it only detects up to two targets within a single reaction.  It is a critical shortcoming 
when working with large sample numbers and low availability of sample volume, which is typical 
for single cell analysis. To increase analytic capacity, future studies should focus on the 
implementation of multiplex dPCR that enables simultaneous mutation analysis on multiple targets 
without compromising the sensitivity and specificity. Optimization of multiplex dPCR protocol is 
currently underway in our lab. 
Finally, another critical goal of a future study could be to extrapolate the proposed workflow to 
EV molecular analysis. Similar to single cell analysis, molecular analysis of EVs is also facing 
hurdles in retrieving and analyzing RNA from small sample inputs. Given the successful 
implementation of the workflow for sorting and characterizing CTCs at a single-cell resolution, 
future efforts should adapt and further optimize the single cell analysis workflow to EV studies. 
This can be accomplished by incorporating technologies and protocols for EV isolation and then 
optimizing their compatibilities with current workflow. 
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5.3    Conclusion 
Overall, the current thesis work performed has developed new technologies and approaches to 
analyze CTCs and EVs at molecular level. Further improvement will help the transition of these 
technologies from laboratory research into clinical application, thus facilitating the development 
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